Separate Interim Financial Statements

September 30, 2017 and 2016

(Unaudited)

(With Independent Auditors' Review Report Thereon)

Contents

	Page
Independent Auditors' Review Report	1
Separate Interim Financial Statements	
Separate Interim Statements of Financial Position	3
Separate Interim Statements of Comprehensive Income	5
Separate Interim Statements of Changes in Equity	7
Separate Interim Statements of Cash Flows	10
Notes to the Separate Interim Financial Statements	11

Independent Auditors' Review Report

Based on a report originally issued in Korean

The Board of Directors and Shareholders KT&G Corporation:

Reviewed financial statements

We have reviewed the accompanying separate interim financial statements of KT&G Corporation (the "Company"), expressed in Korean won, which comprise the separate interim statement of financial position as of September 30, 2017, the separate interim statements of comprehensive income for the three- and nine-month periods ended September 30, 2017 and 2016, the separate interim statements of changes in equity and cash flows for the nine-month periods ended September 30, 2017 and 2016 and notes, comprising a summary of significant accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these separate interim financial statements in accordance with Korean International Financial Reporting Standards ("K-IFRS") No.1034 *Interim Financial Reporting*, and for such internal control as management determines is necessary to enable the preparation of separate interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' review responsibility

Our responsibility is to issue a report on these separate interim financial statements based on our reviews.

We conducted our reviews in accordance with the Review Standards for Quarterly and Semi-annual Financial Statements established by the Securities and Futures Commission of the Republic of Korea. A review of separate interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Korean Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying separate interim financial statements referred to above are not prepared, in all material respects, in accordance with K-IFRS No.1034 *Interim Financial Reporting*.

The accompanying separate interim financial statements as of and for the three- and nine-month periods ended September 30, 2017 have been translated into United States dollars solely for the convenience of the reader and such translation does not comply with K-IFRS. We have reviewed the translation and nothing came to our attention that causes us to believe that the separate interim financial statements expressed in Korean won have not been translated into dollars on the basis set forth in note 4 to the separate interim financial statements.

Other matters

The procedures and practices utilized in the Republic of Korea to review such separate interim financial statements may differ from those generally accepted and applied in other countries.

The separate statement of financial position of the Company as of December 31, 2016, and the related separate statements of comprehensive income, changes in equity and cash flows for the year then ended, which are not accompanying this report, were audited by us in accordance with Korean Standards on Auditing and our report thereon, dated February 24, 2017, expressed an unqualified opinion. The accompanying separate statement of financial position of the Company as of December 31, 2016, presented for comparative purposes, is consistent, in all material respects, with the audited separate financial statements from which it has been derived.

KPMG Samjong Accounting Corp. Seoul, Korea November 10, 2017

This report is effective as of November 10, 2017, the review report date. Certain subsequent events or circumstances, which may occur between the review report date and the time of reading this report, could have a material impact on the accompanying separate interim financial statements and notes thereto. Accordingly, the readers of the review report should understand that the above review report has not been updated to reflect the impact of such subsequent events or circumstances, if any.

KT&G CORPORATION Separate Interim Statements of Financial Position (Unaudited)

As of September 30, 2017 and December 31, 2016

		September 30, 2017	September 30, 2017	December 31, 2016
In millions of won		Z017 Korean	U.S. dollars	Korean
and thousands of U.S. dollars	Note	won	(note 4)	won
Assets				
Property, plant and equipment	5	₩ 1,216,645	\$ 1,060,996	₩ 1,117,268
Intangible assets	6	26,766	23,342	28,928
Investment property	7,16	327,967	286,010	335,196
Investments in associates and joint ventures	8,30	51,930	45,286	58,230
Investments in subsidiaries	9,30	1,272,949	1,110,097	1,154,925
Available-for-sale financial assets	10,31	435,158	379,487	364,305
Long-term deposits in MSA Escrow Fund	11,31,33	535,663	467,135	503,592
Long-term prepaid expenses		4,478	3,905	5,398
Other financial assets	14,15,31,33	6,340	5,531	-
Long-term trade and other receivables	12,16,30,31	57,677	50,297	68,017
Total non-current assets		3,935,573	3,432,086	3,635,859
Inventories	13	756,240	659,493	914,702
Current available-for-sale financial assets	10,31	-	-	1,500
Current other financial assets	14,31,32,34	1,260,000	1,098,805	1,620,000
Prepaid tobacco excise and other taxes		353,327	308,124	439,413
Trade and other receivables	12,24,30,31	1,278,092	1,114,583	1,140,598
Advance payments		44,041	38,407	22,272
Prepaid expenses		3,182	2,775	5,733
Cash and cash equivalents	14,31,32	1,143,361	997,088	688,735
Total current assets		4,838,243	4,219,275	4,832,953
Total assets		₩ 8,773,816	\$ 7,651,360	₩ 8,468,812

Separate Interim Statements of Financial Position, Continued (Unaudited)

As of September 30, 2017 and December 31, 2016

		September 30,	The second secon	December 31,
In millions of won		2017 Korean	2017 U.S. dollars	2016 Korean
and thousands of U.S. dollars	Note	won	(note 4)	won
Finale.			, , , , , ,	
Equity	1 17	\\\\ OE 4 OE 0	Φ 000 700	\\\\ \OE4.0E0
Ordinary shares	1,17	₩ 954,959	\$ 832,789	₩ 954,959
Other capital surplus	17	3,582	3,124	3,582
Treasury shares	18	(328,157)	(286,175)	(328,157)
Gain on reissuance of treasury shares	18	513,776	448,047	513,776
Reserves	19	5,009,802	4,368,886	4,366,268
Retained earnings	20	785,714	685,196	1,068,469
Total equity		6,939,676	6,051,867	6,578,897
Liabilities				
Long-term trade and other payables	16,21,30,31	12,362	10,780	6,848
Long-term advance receipts		687	599	319
Net defined benefit liability	23	67,324	58,711	47,121
Deferred income tax liabilities		73,603	64,187	73,328
Total non-current liabilities		153,976	134,277	127,616
Short-term borrowings	22,31,32	2,790	2,433	3,851
Trade and other payables	16,21,30,31	392,751	342,505	436,270
Advance receipts		1,304	1,137	972
Income tax payable		173,484	151,290	174,192
Tobacco excise and other taxes payable		1,109,835	967,851	1,147,014
Total current liabilities		1,680,164	1,465,216	1,762,299
Total liabilities		1,834,140	1,599,494	1,889,915
Total equity and liabilities		₩ 8,773,816	\$ 7,651,361	₩ 8,468,812

Separate Interim Statements of Comprehensive Income

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

In millions of won			2017		2017		2016
and thousands of U.S. dollars, except earnings per share	Note		Korean won		U.S. dollars (note 4)		Korean won
			VVOIT		(Hote 4)		VVOIT
Sales:	24,30,33	۱۸/ ۱	2 060 400	Φ.	1 004 724	١٨/	0 010 771
Manufacture of tobacco Real estate		VV 2	2,069,489	Ф	1,804,734	∨∨ .	
			140,004 107,250		122,093 93,529		106,665 81,124
Exports of leaf tobacco and others		,	2,316,743	,	2,020,356		2,200,560
		- 1	2,510,745		2,020,330		2,200,300
Cost of sales:	24,25,30				/==== ===×		/0.40 = 0.41
Manufacture of tobacco			(675,777)		(589,323)		(643,704)
Real estate			(88,812)		(77,450)		(62,156)
Exports of leaf tobacco and others			(70,896)		(61,826)		(48,631)
			(835,485)		(728,599)		(754,491)
Gross profit		•	1,481,258	•	1,291,757		1,446,069
Selling, general and administrative expenses	25,30		(479,800)		(418,418)		(446,688)
Operating profit			1,001,458		873,339		999,381
Other income	26,30		34,558		30,137		44,383
Other expenses	26,30		(92,205)		(80,409)		(112,987)
Finance income	27,31		117,633		102,584		44,135
Finance costs	27,31		(18,906)		(16,487)		(502)
Net finance income	27,31		98,727		86,097		43,632
Profit before income tax			1,042,538		909,164		974,409
Income tax expense	28		(256,466)		(223,656)		(236,405)
Profit for the period		₩	786,072	\$	685,508	₩	738,004
Other comprehensive income (loss):							
Items that will not be reclassified to profit or loss							
Remeasurements of							
net defined benefit liability, net of tax		₩	(358)	\$	(312)	₩	(17)
Items that are or may be							
reclassified subsequently to profit or loss							
Unrealized net changes in fair value of							
available-for-sale financial assets, net of tax			29,619		25,830		2,300
Other comprehensive income							
for the period, net of tax			29,261		25,518		2,283
Total comprehensive income for the period		₩	815,333	\$	711,026	₩	740,288
Earnings per share in won and U.S. dollars:							
Basic and diluted	29	₩	6,226	\$	5.43	₩	5,851

Separate Interim Statements of Comprehensive Income, Continued (Unaudited)

For the three-month periods ended September 30, 2017 and 2016

In millions of won and thousands of U.S. dollars, except earnings per share	lote		2017 Korean won	2017 U.S. dollars (note 4)		2016 Korean won
Sales: 24,30	,33					
Manufacture of tobacco		₩	713,326	\$ 622,068	₩	695,018
Real estate			41,152	35,888		32,422
Exports of leaf tobacco and others			35,017	30,537		26,386
			789,495	688,493		753,826
Cost of sales: 24,25	,30					
Manufacture of tobacco			(234,840)	(204,797)		(220,465)
Real estate			(25,024)	(21,823)		(18,267)
Exports of leaf tobacco and others			(23,529)	(20,519)		(15,631)
			(283,393)	(247,139)		(254,363)
Gross profit			506,102	441,354		499,463
·	,30		(167,625)	(146,180)		(150,180)
Operating profit			338,477	295,174		349,283
Other income 26	,30		20,876	18,206		6,958
	,30		(12,604)	(10,992)		(89,849)
Finance income 27	,31		14,110	12,305		9,874
Finance costs 27	,31		(3,739)	(3,260)		(157)
Net finance income	27		10,371	9,045		9,717
Profit before income tax			357,120	311,433		276,109
Income tax expense	28		(87,649)	(76,436)		(68,120)
Profit for the period		₩	269,471	\$ 234,997	₩	207,989
Other comprehensive income (loss):						
Items that will not be reclassified to profit or loss						
Remeasurements of						
net defined benefit liability, net of tax		₩	41	\$ 35	₩	62
Items that are or may be						
reclassified subsequently to profit or loss						
Unrealized net changes in fair value of						
available-for-sale financial assets, net of tax			1,651	1,440		6,880
Other comprehensive income						
for the period, net of tax			1,692	1,475		6,942
Total comprehensive income for the period		₩	271,163	\$ 236,472	₩	214,931
Earnings per share in won and U.S. dollars:						
Basic and diluted	29	₩	2,134	\$ 1.86	₩	1,649

Separate Interim Statements of Changes in Equity

(Unaudited)

For the nine-month period ended September 30, 2017

			Other	,	Gain on reissuance of			
In millions of won		Ordinary shares	capital surplus	Treasury shares	treasury	Reserves	Retained earnings	Total equity
Balance at January 1, 2017	₩	954,959	3,582	(328,157)	513,776			6,578,897
Total comprehensive income for the period: Profit for the period		-	-	-	-	-	786,072	786,072
Other comprehensive income (loss): Remeasurements of net defined benefit liability, net of tax Unrealized net changes in fair value of		-	-	-	-	-	(358)	
available-for-sale financial assets, net of tax		-	-	-	-	29,619	-	29,619
Total other comprehensive income (loss)		-	-	-	-	29,619	(358)	29,261
Total comprehensive income for the period		-	_	-	_	29,619	785,714	815,333
Transactions with owners, recorded directly in equity: Dividends Transfer from reserve for research and human resource development		- -	-	- -	-	- (10,000)	(454,554) 10,000	(454,554)
Transfer to unconditional reserve		-	-	-	-	623,915	(623,915)	_
Total transactions with owners		-	-	-	-	613,915	(1,068,469)	(454,554)
Balance at September 30, 2017	₩	954,959	3,582	(328,157)	513,776	5,009,802	785,714	6,939,676

See accompanying notes to the separate interim financial statements.

Separate Interim Statements of Changes in Equity, Continued

(Unaudited)

For the nine-month period ended September 30, 2017

	Ordinary	Other capital	r Treasury	Gain on reissuance of treasury		Retained	Total
In thousands of U.S. dollars (note 4)	shares	surplus	shares	shares	Reserves	earnings	equity
Balance at January 1, 2017	\$ 832,789	3,124	(286,175)	448,047	3,807,681	931,777	5,737,243
Total comprehensive income for the period: Profit for the period	-	_	-	_	-	685,508	685,508
Other comprehensive income (loss): Remeasurements of net defined benefit liability, net of tax Unrealized net changes in fair value of	-	-	-	-	-	(312)	
available-for-sale financial assets, net of tax	-	-	-	=,	25,830	=	25,830
Total other comprehensive income (loss)		-			25,830	(312)	25,518
Total comprehensive income for the period	-	-	-	-	25,830	685,196	711,026
Transactions with owners, recorded directly in equity: Dividends	-	<u>.</u> -	-	-	-	(396,402)	(396,402)
Transfer from reserve for research and human resource development Transfer to unconditional reserve	-	-	-	-	(8,721) 544,096	8,721 (544,096)	-
Total transactions with owners	-	-	-	-	535,375	(931,777)	(396,402)
Balance at September 30, 2017	\$ 832,789	3,124	(286,175)	448,047	4,368,886	685,196	6,051,867

See accompanying notes to the separate interim financial statements.

Separate Interim Statements of Changes in Equity, Continued

(Unaudited)

For the nine-month period ended September 30, 2016

			Other	,	Gain on reissuance of			
		Ordinary	capital	Treasury	treasury		Retained	Total
In millions of won		shares	surplus	shares	shares	Reserves	earnings	equity
Balance at January 1, 2016	₩	954,959	3,582	(337,062)	494,648	3,784,467	995,887	5,896,481
Total comprehensive income for the period: Profit for the period		-	-	-	-	-	738,004	738,004
Other comprehensive loss: Remeasurements of net defined benefit liability, net of tax Unrealized net changes in fair value of		-	-	-	-	-	(17)	(17)
available-for-sale financial assets, net of tax		-	-	-	-	2,300	-	2,300
Total other comprehensive loss			•			2,300	(17)	2,283
Total comprehensive income for the period		_	_	-	_	2,300	737,987	740,287
Transactions with owners, recorded directly in equity:								
Dividends		-		-	-	-	(428,284)	(428,284)
Donation of treasury shares		-	-	5,290	10,543	-	-	15,833
Transfer from reserve for research and human resource development		-	_	-	-	(10,000)	10,000	-
Transfer to unconditional reserve			-		-	577,602	(577,602)	
Total transactions with owners		-	-	5,290	10,543	567,602	(995,886)	(412,451)
Balance at September 30, 2016	₩	954,959	3,582	(331,772)	505,191	4,354,369	737,988	6,224,317

See accompanying notes to the separate interim financial statements.

KT&G CORPORATION Separate Interim Statements of Cash Flows

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

In millions of won		2017 Korean	2017 U.S. dollars		2016 Korean
and thousands of U.S. dollars	Note	won	(note 4)		Won
Cash flows from operating activities					
Cash generated from operations	34	₩ 1,040,313	\$ 907,224	₩	892,745
Income tax paid		(266,240)	(232,180)		(349,318)
Net cash provided by operating activities		774,073	675,044		543,427
Cash flows from investing activities	34				
Interest received		33,598	29,300		27,086
Dividends received		82,599	72,032		13,798
Proceeds from sale of property, plant and equipment		3,052	2,662		10,671
Proceeds from sale of intangible assets		1,350	1,178		182
Proceeds from sale of non-current assets held for sale		-	-		5,800
Proceeds from sale of available-for-sale financial assets		3,462	3,019		-
Proceeds from investments in associates and joint ventures		7,319	6,382		13,095
Proceeds from investments in subsidiaries		17,724	15,456		-
Collection of loans		10,389	9,060		10,287
Withdrawal of guarantee deposits		15,440	13,465		10,781
Acquisition of property, plant and equipment		(172,481)	(150,415)		(84,223)
Acquisition of intangible assets		(1,742)	(1,519)		(5,826)
Acquisition of investments in associates and joint ventures		(1,000)	(872)		-
Acquisition of investments in subsidiaries		(97,202)	(84,767)		(1,500)
Acquisition of available-for-sale financial assets		(52,946)	(46,173)		(15,000)
Payments of guarantee deposits		(17,049)	(14,868)		(17,802)
Payments of long-term deposits in MSA Escrow Fund		(57,338)	(50,003)		(68,897)
Decrease in current other financial assets, net		353,660	308,416		10,000
Net cash provided by investing activities		128,835	112,353		(91,548)
Cash flows from financing activities	34				
Dividends paid		(454,554)	(396,402)		(428,284)
Increase in deposits received		8,192	7,145		1,764
Decrease in deposits received		(2,190)	(1,910)		(2,274)
Net cash provided by (used in) financing activities		(448,552)	(391,167)		(428,794)
Effect of exchange rate fluctuation on cash held		270	235		(171)
Net increase in cash and cash equivalents		454,626	396,465		22,914
Cash and cash equivalents at January 1		688,735	600,624		444,376
Cash and cash equivalents at September 30		₩ 1,143,361	\$ 997,089	₩	467,290

For the nine-month periods ended September 30, 2017 and 2016

1. Organization and Description of Business

KT&G Corporation (the "Company"), which is engaged in manufacturing and selling tobaccos, was established on April 1, 1987 as Korea Monopoly Corporation, a wholly-owned enterprise of the Korean government, pursuant to the Korea Monopoly Corporation Act, in order to secure financing and to promote and develop, through efficient management, the monopoly business of red ginseng and tobacco. On April 1, 1989, the Company changed its name to Korea Tobacco and Ginseng Corporation pursuant to the Korea Tobacco and Ginseng Corporation Act. Also, pursuant to the Act on Management Reform and Privatization of Public Enterprises, proclaimed on August 28, 1997 and enforced on October 1, 1997, the Company was excluded from the application of the Act for the Management of Government Invested Enterprises. Accordingly, the Company became an entity existing and operating under the Commercial Act of Korea. The Korean government sold 28,650,000 shares of the Company to the public during 1999 and the Company listed its shares on the Korea Exchange on October 8, 1999. On December 27, 2002, the Company changed its name again to KT&G Corporation from Korea Tobacco and Ginseng Corporation.

As of September 30, 2017, the Company has three manufacturing plants, including the Shintanjin plant, and 14 local headquarters and 123 branches for the sale of tobacco throughout the country. Also, the Company has the Gimcheon plant for fabrication of leaf tobacco and the Cheonan printing plant for the manufacturing of packaging. The head office of the Company is located at 71, Beotkkot-gil, Daedeok-gu, Daejeon.

Pursuant to the Korean government's privatization program and management reorganization plan, on December 28, 1998, the shareholders approved a plan to split the Company into two companies by setting up a subsidiary for its red ginseng business segment effective January 1, 1999. The separation was accomplished by the Company's contribution of the assets and liabilities in the red ginseng business segment into a wholly-owned subsidiary, Korea Ginseng Corporation.

On October 17, 2002 and October 31, 2001, the Company listed 35,816,658 and 45,400,000 Global Depositary Receipts ("GDR") (each GDR representing the right to receive one-half share of an ordinary share of the Company), respectively, on the Luxembourg Stock Exchange pursuant to the Korean government's privatization program. Also, on June 25, 2009, the market of the Company's GDR was changed from the BdL market to the Euro MTF in the Luxembourg Stock Exchange.

The ownership of the Company's issued ordinary shares as of September 30, 2017 is held as follows:

Shareholder	Number of shares	Percentage of ownership
National Pension Service	12,482,705	9.09%
Industrial Bank of Korea	9,510,485	6.93%
Employee Share Ownership Association	2,827,708	2.06%
Treasury shares	11,027,370	8.03%
Others	101,444,229	73.89%
	137,292,497	100.00%

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

2. Basis of Preparation

(a) Statement of Compliance

The separate interim financial statements have been prepared in accordance with Korean International Financial Reporting Standards ("K-IFRS") as prescribed in *the Act on External Audits of Corporations*.

These separate interim financial statements were prepared in accordance with K-IFRS No. 1034 *Interim Financial Reporting* as part of the period covered by the Company's K-IFRS annual separate financial statements.

These interim financial statements are separate interim financial statements prepared in accordance with K-IFRS No.1027 *Separate Financial Statements* presented by a parent, an investor in an associate or a venture in a jointly controlled entity, in which the investments are accounted for on the basis of the direct equity interest rather than on the basis of the reported results and net assets of the investees.

The separate interim financial statements were authorized for issue by the Board of Directors on October 26, 2017.

(b) Basis of Measurement

The separate interim financial statements have been prepared on the historical cost basis, except for the following material items in the separate interim statements of financial position:

- Available-for-sale financial assets measured at fair value
- Liabilities for defined benefit plans recognized at the net of the total present value of defined benefit obligations less the fair value of plan assets

(c) Functional and Presentation Currency

These separate interim financial statements are presented in Korean won, which is the Company's functional currency and the currency of the primary economic environment in which the Company operates.

(d) Use of Estimates and Judgments

The preparation of the separate interim financial statements in conformity with K-IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

In preparing these separate interim financial statements, the significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial statements as of and for the year ended December 31, 2016.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies

The accounting policies, except for the application of the amendment standard effective from January 1, 2017, set out below have been applied consistently to all periods presented in these separate interim financial statements.

- K-IFRS 1007, 'Statement of Cash Flows'

Amendments to K-IFRS 1007 clarify that the changes in liabilities arising from financing activities are disclosed separately by changes arising from cash flows and non-cash changes and etc. The amendments does not have a material impact on the Company's financial statements.

- K-IFRS 1012, 'Income Taxes'

Amendments to K-IFRS 1012 clarify that the existence of a deductible temporary difference depends solely on a comparison of the carrying amount of and asset and its tax base at the end of the reporting period. The amendments does not have a material impact on the Company's financial statements.

The significant accounting policies applied by the Company in preparation of its separate interim financial statements are included below.

(a) Subsidiaries, Associates and Joint Ventures in the Separate Financial Statements

These separate interim financial statements are prepared and presented in accordance with K-IFRS No.1027. The Company applied the cost method to investments in subsidiaries, associates and joint ventures in accordance with K-IFRS No. 1027. Dividends from a subsidiaries, associates and joint ventures are recognized in profit or loss when the right to receive the dividend is established.

(b) Property, Plant and Equipment

All property, plant and equipment are stated at historical cost less depreciation and accumulated impairment loss. Historical cost includes expenditures directly attribute to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to the statement of comprehensive income during the financial period in which they are incurred.

Property, plant and equipment, except for land and other tangible fixed assets and constituted of tree and others, are depreciated on a straight-line basis over estimated useful lives that appropriately reflect the pattern in which the asset's future economic benefits are expected to be consumed.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(b) Property, Plant and Equipment, Continued

The estimated useful lives of the Company's assets are as follows:

	Useful lives (years)		Useful lives (years)
Buildings	10 ~ 60	Vehicles	4
Structures	10 ~ 40	Tools	4
Machinery	10 ~ 12	Furniture and fixtures	4

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in other income and expense in the statement of comprehensive income.

(c) Borrowing Costs

The Company capitalizes borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset as part of the cost of that asset. Other borrowing costs are recognized in expense as incurred. A qualifying asset is an asset that requires a substantial period of time to get ready for its intended use or sale. Financial assets and inventories that are manufactured or otherwise produced over a short period of time are not qualifying assets. Assets that are ready for their intended use or sale when acquired are not qualifying assets.

To the extent that the Company borrows funds specifically for the purpose of obtaining a qualifying asset, the Company determines the amount of borrowing costs eligible for capitalization as the actual borrowing costs incurred on that borrowing during the period less any investment income on the temporary investment of those borrowings. The Company immediately recognizes other borrowing costs as an expense. To the extent that the Company borrows funds generally and uses them for the purpose of obtaining a qualifying asset, the Company determines the amount of borrowing costs eligible for capitalization by applying a capitalization rate to the expenditures on that asset. The capitalization rate is the weighted average of the borrowing costs applicable to the borrowings of the Company that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. The amount of borrowing costs that the Company capitalizes during a period does not exceed the amount of borrowing costs incurred during that period.

(d) Government Grants

Government grants are not recognized unless there is reasonable assurance that the Company will comply with the grant's conditions and that the grant will be received. Government grants which are intended to compensate the Company for expenses incurred are recognized as other income in profit or loss over the periods in which the Company recognizes the related costs as expenses.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(e) Intangible Assets

Intangible assets are measured initially at cost and, subsequently, are carried at cost less accumulated amortization and accumulated impairment losses. Intangible assets consist of industrial property rights, facility usage rights and intangible assets under development. Intangible assets are amortized on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use. The residual value of intangible assets is assumed to be zero. However, as there are no foreseeable limits to the periods over which some of industrial property rights and facility usage rights are expected to be available for use, these intangible assets are regarded as having indefinite useful lives and not amortized.

The estimated useful lives are as follows:

	Useful lives (years)
Industrial property rights Facility usage rights	10 ~ 20 or indefinite indefinite

Amortization periods and amortization methods for intangible assets with finite useful lives are reviewed at the end of each reporting period. The useful lives of intangible assets that are not being amortized are reviewed at the end of each reporting period to determine whether events and circumstances continue to support indefinite useful life assessment for those assets. The change is accounted for as a change in an accounting estimate.

(f) Investment Property

Property held for the purpose of earning rentals or benefiting from capital appreciation is classified as investment property. Investment property is initially measured at its cost. Transaction costs are included in the initial measurement. Subsequently, investment property is carried at depreciated cost less any accumulated impairment losses.

Subsequent costs are recognized in the carrying amount of investment property at cost or, if appropriate, as separate items if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing are recognized in profit or loss as incurred.

Investment property except for land, are depreciated on a straight-line basis over 10 ~ 60 years as estimated useful lives.

Depreciation methods, useful lives and residual values are reviewed at the end of each reporting period and adjusted, if appropriate. The change is accounted for as a change in an accounting estimate.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(g) Non-current Assets Held for Sale

Non-current assets, or disposal groups comprising assets and liabilities, that are expected to be recovered primarily through sale rather than through continuing use, are classified as held for sale. In order to be classified as held for sale, the asset (or disposal group) must be available for immediate sale in its present condition and its sale must be highly probable. The assets or disposal group that are classified as non-current assets held for sale are measured at the lower of their carrying amount and fair value less cost to sell.

The Company recognizes an impairment loss for any initial or subsequent write-down of an asset (or disposal group) to fair value less costs to sell, and a gain for any subsequent increase in fair value less costs to sell, up to the cumulative impairment loss previously recognized in accordance with K-IFRS No. 1036 *Impairment of Assets*.

A non-current asset that is classified as held for sale or part of a disposal group classified as held for sale is not depreciated (or amortized).

(h) Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

The cost of inventories is determined by the weighted-average method for finished goods, by-products, work-in-progress and tobacco leaf in raw materials, by the moving-average method for raw materials and supplies; and by the specific identification method for all other inventories.

When inventories are sold, the carrying amount of those inventories is recognized as an expense in the period in which the related revenue is recognized. The amount of any write-down of inventories to net realizable value and all losses of inventories are recognized as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realizable value, is recognized as a reduction in the amount of inventories and recognized as an expense in the period in which the reversal occurs.

Tobacco leaf inventories which have an operating cycle that exceeds 12 months are classified as current assets, consistent with recognized industry practice. The estimated amounts of inventories in current assets which are not expected to be consumed within 12 months are \text{\psi}252,897 million and \text{\psi}314,457 million, respectively, as of September 30, 2017 and December 31, 2016.

(i) Impairment of Non-financial Assets

The carrying amounts of the Company's non-financial assets, other than inventories, deferred tax assets, assets arising from employee benefits and non-current assets held for sale, are reviewed at the end of the reporting period to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. Goodwill and intangible assets that have indefinite useful lives or that are not yet available for use, irrespective of whether there is any indication of impairment, are tested for impairment annually by comparing their recoverable amount to their carrying amount.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(i) Impairment of Non-financial Assets, Continued

The Company estimates the recoverable amount of an individual asset. If it is impossible to measure the individual recoverable amount of an asset, then the Company estimates the recoverable amount of cash-generating unit ("CGU"). A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. The value in use is estimated by applying a pre-tax discount rate that reflect current market assessments of the time value of money and the risks specific to the asset or CGU for which estimated future cash flows have not been adjusted, to the estimated future cash flows expected to be generated by the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or a CGU exceeds its recoverable amount. Impairment losses are recognized in profit or loss.

(i) Non-derivative Financial Assets

The Company recognizes and measures non-derivative financial assets by the following four categories: financial assets at fair value through profit or loss, held-to-maturity investments, loans and receivables and available-for-sale financial assets. The Company recognizes financial assets in the statement of financial position when the Company becomes a party to the contractual provisions of the instrument.

Upon initial recognition, non-derivative financial assets are measured at their fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the asset's acquisition or issuance.

(i) Financial assets at fair value through profit or loss

A financial asset is classified as financial assets are classified at fair value through profit or loss if it is held for trading or is designated as such upon initial recognition. Upon initial recognition, transaction costs are recognized in profit or loss when incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein are recognized in profit or loss.

(ii) Held-to-maturity investments

A non-derivative financial asset with a fixed or determinable payment and fixed maturity, for which the Company has the positive intention and ability to hold to maturity, are classified as held-to-maturity investments. Subsequent to initial recognition, held-to-maturity investments are measured at amortized cost using the effective interest method.

(iii) Loans and receivables

Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method except for loans and receivables of which the effect of discounting is immaterial.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(j) Non-derivative Financial Assets, Continued

(iv) Available-for-sale financial assets

Available-for-sale financial assets are those non-derivative financial assets that are designated as available-for-sale or are not classified as financial assets at fair value through profit or loss, held-to-maturity investments or loans and receivables. Subsequent to initial recognition, they are measured at fair value, which changes in fair value, net of any tax effect, recorded in other comprehensive income in equity. Investments in equity instruments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured and derivatives that are linked to and must be settled by delivery of such unquoted equity instruments are measured at cost.

(v) De-recognition of financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

If the Company retains substantially all the risks and rewards of ownership of the transferred financial assets, the Company continues to recognize the transferred financial assets and recognizes financial liabilities for the consideration received

(vi) Offsetting between financial assets and financial liabilities

Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position only when the Company currently has a legally enforceable right to offset the recognized amounts, and there is the intention to settle on a net basis or to realize the asset and settle the liability simultaneously.

(k) Derivative Financial Instruments

Derivatives are initially recognized at fair value. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized immediately in profit or loss.

Embedded derivatives are separated from the host contract and accounted for separately only if the following criteria have been met:

- the economic characteristics and risks of the embedded derivative are not closely related to those of the host contract
- a separate instrument with the same terms as the embedded derivative would meet the definition of a
 derivative and
- the hybrid instrument is not measured at fair value with changes in fair value recognized in profit or loss.

Changes in the fair value of separable embedded derivatives are recognized immediately in profit or loss.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(I) Impairment of Financial Assets

A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. However, losses expected as a result of future events, regardless of likelihood, are not recognized.

If financial assets have objective evidence that they are impaired, impairment losses should be measured and recognized.

(i) Financial assets measured at amortized cost

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of its estimated future cash flows discounted at the asset's original effective interest rate. If it is not practicable to obtain the instrument's estimated future cash flows, impairment losses would be measured by using prices from any observable current market transactions. The Company can recognize impairment losses directly or establish a provision to cover impairment losses. If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed either directly or by adjusting an allowance account.

(ii) Financial assets carried at cost

If there is objective evidence that an impairment loss has occurred on an unquoted equity instrument that is not carried at fair value because its fair value cannot be reliably measured, or on a derivative asset that is linked to and must be settled by delivery of such an unquoted equity instrument, the amount of the impairment loss is measured as the difference between the carrying amount of the financial asset and the present value of estimated future cash flows discounted at the current market rate of return for a similar financial asset. Such impairment losses are not reversed.

(iii) Available-for-sale financial assets

When a decline in the fair value of an available-for-sale financial asset has been recognized in other comprehensive income and there is objective evidence that the asset is impaired, the cumulative loss that had been recognized in other comprehensive income is reclassified from other comprehensive income to profit or loss as a reclassification adjustment even though the financial asset has not been derecognized. Impairment losses recognized in profit or loss for an investment in an equity instrument classified as available-for-sale are not reversed through profit or loss. If, in a subsequent period, the fair value of a debt instrument classified as available-for-sale increases and the increase can be objectively related to an event occurring after the impairment loss was recognized in profit or loss, the impairment loss is reversed, with the amount of the reversal recognized in profit or loss. For an investment in an equity security, objective evidence of impairment includes a significant or prolonged decline in its fair value below its cost. The Company considers a decline of 20% to be significant and a period of nine months to be prolonged.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(m) Cash and Cash Equivalents

Cash and cash equivalents comprise cash balances and call deposits with maturities of three months or less from the acquisition date that are subject to an insignificant risk of changes in their fair value, and are used by the Company in the management of its short-term commitments. Equity investments are excluded from cash equivalents unless they are, in substance, cash equivalents, for example in the case of preferred shares when it has a short maturity with a specified redemption date.

(n) Non-derivative Financial Liabilities

The Company classifies non-derivative financial liabilities into financial liabilities at fair value through profit or loss, financial guarantee liabilities and other financial liabilities in accordance with the substance of the contractual arrangement and the definitions of financial liabilities. The Company recognizes financial liabilities in the statement of financial position when the Company becomes a party to the contractual provisions of the financial liability.

(i) Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading or designated as such upon initial recognition. Subsequent to initial recognition, financial liabilities at fair value through profit or loss are measured at fair value, and changes therein are recognized in profit or loss. Upon initial recognition, transaction costs that are directly attributable to the acquisition are recognized in profit or loss as incurred.

(ii) Financial guarantee liabilities

Financial guarantee liability is a contract that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payment when due in accordance with the original or modified term of a debt instrument. Upon initial recognition, financial guarantee liabilities are measured at their fair value plus, transaction costs that are directly attributable to the acquisition or issue of the financial guarantee liability.

After initial recognition, an issuer of such a contract measures it at the higher of the amount determined in accordance with K-IFRS No. 1037 *Provisions, Contingent Liabilities and Contingent Assets* and the amount initially recognized less, when appropriate, cumulative amortisation recognized in accordance with K-IFRS No. 1018 *Revenue*.

(iii) Other financial liabilities

Non-derivative financial liabilities other than financial liabilities at fair value through profit or loss or financial guarantee liabilities are classified as other financial liabilities. At the date of initial recognition, other financial liabilities are measured at fair value minus transaction costs that are directly attributable to the acquisition. Subsequent to initial recognition, other financial liabilities are measured at amortized cost using the effective interest method.

The Company derecognizes a financial liability from the statement of financial position when it is extinguished (i.e. when the obligation specified in the contract is discharged, cancelled or expires).

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(o) Employee Benefits

(i) Short-term employee benefits

Short-term employee benefits are employee benefits that are due to be settled within 12 months after the end of the period in which the employees render the related service. When an employee has rendered service to the Company during an accounting period, the Company recognizes the undiscounted amount of short-term employee benefits expected to be paid in exchange for that service.

(ii) Retirement benefits: defined contribution plans

When an employee has rendered service to the Company during a period, the Company recognizes the contribution payable to a defined contribution plan in exchange for that service as a liability (accrued expense), after deducting any contribution already paid. If the contribution already paid exceeds the contribution due for service before the end of the reporting period, the Company recognizes that excess as an asset (prepaid expense) to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

(iii) Retirement benefits: defined benefit plans

The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in other comprehensive income. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the year by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in profit or loss. The Company recognizes gains and losses on the settlement of a defined benefit plan when the settlement occurs.

(iv) Termination benefits

Termination benefits are expensed at the earlier of when the Company can no longer withdraw the offer of those benefits and when the Company recognizes costs for a restructuring. If benefits are not expected to be settled wholly within 12 months of the end of the reporting period, they are discounted.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(p) Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The risks and uncertainties that inevitably surround many events and circumstances are taken into account in reaching the best estimate of a provision. Where the effect of the time value of money is material, provisions are determined at the present value of the expected future cash flows.

Where some or all of the expenditures required to settle a provision are expected to be reimbursed by another party, the reimbursement shall be recognized when, and only when, it is virtually certain that reimbursement will be received if the entity settles the obligation. The reimbursement shall be treated as a separate asset.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimates. If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed.

(q) Equity Capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects.

When the Company repurchases its share capital, the amount of the consideration paid is recognized as a deduction from equity and classified as treasury shares. The profits or losses from the purchase, disposal, reissue, or retirement of treasury shares are not recognized as current profit or loss. If the Company acquires and retains treasury shares, the consideration paid or received is directly recognized in equity.

(r) Revenue Recognition

The Company's revenue categories consist of goods sold, services and other income.

Revenue from sales of goods is measured at the fair value of the consideration received or receivable, net of tobacco excise and other taxes, trade discounts and volume rebates. Revenue from the sale of goods is recognized when the Company has transferred to the buyer the significant risks and rewards of ownership of the goods, the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the Company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Tobacco excise and other taxes deducted from revenue For the nine-month periods ended September 30, 2017 and 2016 were \$\frac{\text{W}}{4,600,966}\$ million and \$\frac{\text{W4}}{4,656,466}\$ million, respectively.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(r) Revenue Recognition, Continued

Revenue from the construction of real estate includes the initial amount agreed in the contract plus any variations in contract work, claims and incentive payments, to the extent that it is probable that they will result in revenue and can be measured reliably. As soon as the outcome of a construction contract can be estimated reliably, contract revenue is recognized in profit or loss in proportion to the stage of completion of the contract. The stage of completions is assessed by reference to surveys of work performed. Meanwhile, profits from an apartment house for self-instalment sales is recognized on percentage-of-completion method according to Q&A of Korea Accounting Institute, called namely 2011-I-KQA. This accounting treatment is valid only under the K-IFRS as stated in subclause1 of clause 1, Article 13 of the Act on External Audit of Stock companies.

Revenue from rendering of services is recognized by reference to the stage of completion of the transaction at the end of the reporting period when the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the Company, the stage of completion of the transaction at the end of the reporting period can be measured reliably and the costs incurred for the transaction and the costs to complete the transaction can be measured reliably. When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognized only to the extent of the expenses recognized that are recoverable.

Rental income from investment property, net of lease incentives granted, is recognized in profit or loss on a straight-line basis over the term of the lease.

(s) Finance Income and Finance Costs

Finance income comprises interest income on funds invested (including available-for-sale financial assets), dividend income and investment income on long-term deposits in MSA Escrow Fund. Interest income is recognized as it accrues in profit or loss, using the effective interest method. Dividend income is recognized in profit or loss on the date that the Company's right to receive payment is established.

Finance costs is interest expense on unwinding of the discount on trade and other payables which is recognized in profit or loss using the effective interest method.

(t) Income Taxes

Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income.

(i) Current tax

Current tax is the expected tax payable or receivable on the taxable profit or loss for the year, using tax rates enacted or substantively enacted at the end of the reporting period and any adjustment to tax payable in respect of previous years. The taxable profit is different from the accounting profit for the year since the taxable profit is calculated excluding the temporary differences, which will be taxable or deductible in determining taxable profit (tax loss) of future periods, and non-taxable or non-deductible items from the accounting profit.

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(t) Income Taxes, Continued

(ii) Deferred tax

The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. The Company recognizes a deferred tax asset for all deductible temporary differences to the extent that it is probable that the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilized.

The carrying amount of a deferred tax asset is reviewed at the end of each reporting period and reduces the carrying amount to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of that deferred tax asset to be utilized.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if there is a legally enforceable right to offset the related current tax liabilities and assets, and they relate to income taxes levied by the same tax authority and they intend to settle current tax liabilities and assets on a net basis

(u) Foreign Currencies

Transactions in foreign currencies are translated to the respective functional currencies of the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated to the functional currency using the reporting date's exchange rate. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined.

Foreign currency differences arising on retranslation are recognized in profit or loss, except for differences arising on the retranslation of available-for-sale equity instruments, a financial liability designated as a hedge of the net investment in a foreign operation, or qualifying cash flow hedges, which are recognized in other comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

(v) Earnings per Share

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, adjusted for own shares held, for the effects of all dilutive potential ordinary shares.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

3. Significant Accounting Policies, Continued

(w) Operating Segment

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components. All operating segments' operating results are reviewed regularly by the Company's chief executive officer to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

Operating segment disclosures are included in the consolidated financial statements in accordance with K-IFRS No. 1108 *Operating Segments*.

(x) New Standards and Interpretations Not Yet Adopted

The following new standards are effective and earlier application is permitted; however, the Company has not early adopted the following new standards and interpretations in preparing these separate interim financial statements.

K-IFRS No. 1109 Financial Instruments

K-IFRS No. 1109 is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted.

It replaces the existing guidance in K-IFRS No. 1039 *Financial Instruments: Recognition and Measurement.* K-IFRS No. 1109 includes revised guidance on the classification and measurement of financial instruments, a new expected credit loss model for calculating impairment on financial assets, and new general hedge accounting requirements. It also carries forward the guidance on recognition and derecognition of financial instruments from K-IFRS No. 1039.

K-IFRS No. 1115 Revenue from Contracts with Customers

K-IFRS No. 1115 is effective for annual periods beginning on or after January 1, 2018, with early adoption permitted. It replaces existing revenue recognition guidance, including K-IFRS No. 1018 *Revenue*, K-IFRS No. 1011 *Construction Contracts*, K-IFRS No. 2031 *Revenue*—Barter Transactions Involving Advertising Services, K-IFRS No. 2113 *Customer Loyalty Programmes*, K-IFRS No. 2115 *Agreements for the Construction of Real Estate* and K-IFRS No. 2118 *Transfers of Assets from Customers*. K-IFRS No. 1115 establishes a comprehensive framework for determining whether, how much and when revenue is recognized.

The Company currently plans to apply K-IFRS No. 1109 and K-IFRS No. 1115 initially on January 1, 2018. The actual impact of adopting those new standards will be dependent on the financial instruments that the Company holds and economic conditions at that time as well as accounting elections and judgements that it will make in the future. The Company is assessing the potential impact on its separate financial statements resulting from the application of those new standards and expects to disclose additional quantitative information in the separate financial statements for the year ended December 31, 2017.

4. Basis of Translating Financial Statements

The separate interim financial statements are presented in Korean won and have been translated into U.S. dollars at the rate of \(\psi_1\),146.70 to \(\sigma_1\), the basic exchange rate as of September 30, 2017 posted by Seoul Money Brokerage Services, solely for the convenience of the reader. This translation does not comply with K-IFRS and should not be construed as a representation that any or all of the amounts shown could be converted into U.S. dollars at this or any other rate.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

5. Property, Plant and Equipment

(a) Details of property, plant and equipment as of September 30, 2017 and December 31, 2016 are summarized as follows:

			September 30			December 31
_			2017			2016
		Accumulated	Carrying		Accumulated	Carrying
In millions of won	Cost	depreciation	amount	Cost	depreciation	amount
Land W	513,963	-	513,963	426,463	-	426,463
Buildings	716,319	(354,053)	362,266	689,658	(335,706)	353,952
Structures	45,773	(32,445)	13,328	45,467	(30,987)	14,480
Machinery	1,031,046	(842,647)	188,399	1,023,827	(816,628)	207,199
Vehicles	2,423	(1,975)	448	2,293	(1,933)	360
Tools	40,647	(35,767)	4,880	39,406	(34,051)	5,355
Furniture and fixtures	173,991	(137,449)	36,542	166,700	(124,394)	42,306
Others	1,694	-	1,694	1,681	-	1,681
Construction-in-progress	95,125	=	95,125	65,472	-	65,472
₩	2,620,981	(1,404,336)	1,216,645	2,460,967	(1,343,699)	1,117,268

(b) Changes in property, plant and equipment for the nine-month period ended September 30, 2017 were as follows:

In millions of won		January 1 2017	Acquisition	Disposal	Depreciation	Transfer of construction-in-progress	Transfer to investment S property	September 30 2017
Land	W	426,463	4	(245)	-	87,989	(248)	513,963
Buildings		353,952	1,780	(78)	(19,124)	26,298	(562)	362,266
Structures		14,480	285	(47)	(1,512)	125	(3)	13,328
Machinery		207,199	3,079	(1,882)	(32,867)	12,870	-	188,399
Vehicles		360	215	-	(127)	-	-	448
Tools		5,355	921	(28)	(1,819)	451	-	4,880
Furniture and fixtures		42,306	7,918	(44)	(13,859)	221	-	36,542
Others		1,681	13	-	-	-	-	1,694
Construction-in-progress		65,472	157,607	-	-	(127,954)	-	95,125
7	₩	1,117,268	171,822	(2,324)	(69,308)	-	(813)	1,216,645

For the year ended September 30, 2017, land, buildings and structures with a carrying amount of $\frac{1}{2}$ 813 million were transferred to investment property.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

5. Property, Plant and Equipment, Continued

(c) Changes in property, plant and equipment for the year ended December 31, 2016 were as follows:

In millions of won		January 1 2016	Acquisition	Disposal	Depreciation	Transfer of construction-in-progress	Other changes	December 31 2016
Land	₩	467,590	184	(1,685)	-	62,071	(101,697)	426,463
Buildings		385,418	691	(1,336)	(26,772)	101,183	(105,232)	353,952
Structures		15,901	718	(11)	(2,147)	345	(326)	14,480
Machinery		215,984	1,871	(1,349)	(48,013)	38,706	-	207,199
Vehicles		356	339	(165)	(171)	1	-	360
Tools		5,554	1,431	(56)	(2,397)	823	-	5,355
Furniture and fixtures		33,509	24,676	(5,031)	(16,697)	5,849	-	42,306
Others		1,366	9	-	-	306	-	1,681
Construction-in-progress		183,954	90,838	-	-	(209,284)	(36)	65,472
	₩	1,309,632	120,757	(9,633)	(96,197)	-	(207,291)	1,117,268

For the year ended December 31, 2016, the Company received \text{\text{\$\psi}}289 million of government grant related with acquisition of buildings and furniture and fixtures.

For the year ended December 31, 2016, land, buildings and structures with a carrying amount of \(\psi 207,255\) million were transferred to investment property and construction-in-progress with a carrying amount of \(\psi 36\) million were transferred to intangible assets.

6. Intangible Assets

(a) Details of intangible assets as of September 30, 2017 and December 31, 2016 are summarized as follows:

			5		December 31 2016		
In millions of won		Cost	Accumulated amortization	Carrying amount	Cost	Accumulated amortization	Carrying amount
Industrial property rights Facility usage rights Intangible assets	₩	8,644 25,287	(5,584) (1,709)	3,060 23,578	7,718 24,914	(5,556) (1,708)	2,162 23,206
under development		128	-	128	3,560	-	3,560
	₩	34,059	(7,293)	26,766	36,192	(7,264)	28,928

(b) Changes in intangible assets for the nine-month period ended September 30, 2017 were as follows:

		January 1			Transfer from property, plant		September 30
In millions of won		2017	Acquisition	Disposal	and equipment	Amortization	2017
Industrial property rights Facility usage rights Intangible assets	₩	2,162 23,206	226 1,290	- (918)	700	(28)	3,060 23,578
under development		3,560	226	(2,958)	(700)	=	128
	₩	28,928	1,742	(3,876)	-	(28)	26,766

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

6. Intangible Assets, Continued

(c) Changes in intangible assets for the year ended December 31, 2016 were as follows:

In millions of won		January 1 2016	Acquisition	р	Transfer from property, plant nd equipment	Amortization	December 31 2016
Industrial property rights Facility usage rights Intangible assets	₩	1,462 17,472	721 6,189	- (491)	36	(21)	2,162 23,206
under development		3,560	-	-	-	-	3,560
	₩	22,494	6,910	(491)	36	(21)	28,928

(d) Research and development expenditures not capitalized for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Cost of sales	₩	85	134	71	267
Selling, general and administrative expenses		3,943	10,673	2,497	7,178
	₩	4,028	10,807	2,568	7,445

7. Investment Property

(a) Details of investment property as of September 30, 2017 and December 31, 2016 are summarized as follows:

				September 30 2017			December 31 2016
In millions of won		Cost	Accumulated depreciation	Carrying amount	Cost	Accumulated depreciation	Carrying amount
THE THINK OF THE T		0001	doprodiction	arribarre		aoprodiation	arribarre
Land	₩	125,011	-	125,011	124,763	=	124,763
Buildings		280,181	(77,225)	202,956	279,520	(69,087)	210,433
	₩	405,192	(77,225)	327,967	404,283	(69,087)	335,196

(b) Changes in investment property for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

				2017			2016
In millions of won		Land	Buildings	Total	Land	Buildings	Total
Beginning balance Depreciation	₩	124,763	210,433 (8.042)	335,196 (8.042)	23,066	113,735 (8.860)	136,801 (8,860)
Transfer from			(0,042)	(0,042)		(0,000)	(0,000)
property, plant and equipment		248	565	813	101,697	105,558	207,255
Ending balance	₩	125,011	202,956	327,967	124,763	210,433	335,196

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

7. Investment Property, Continued

(c) The amounts recognized in profit or loss from investment property for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won	_	Three-month	Nine-month	Three-month	Nine-month
Rental income Direct operating expense	₩	11,773 (2,666)	33,741 (8,042)	10,020 (2,537)	27,880 (6,249)
	₩	9,107	25,699	7,483	21,631

(d) The carrying amount and the fair value of investment property as of September 30, 2017 and December 31, 2016 were as follows:

			September 30 2017		December 31 2016
	_	Fair	Carrying	Fair	Carrying
In millions of won		value	amount	value	amount
Land	₩	587,391	125,011	532,420	124,763
Buildings		255,635	202,956	227,030	210,433
	₩	843,026	327,967	759,450	335,196

The fair value of investment property was determined based on the yield capitalization method by external, independent valuers. The fair value measurement for all of the investment properties has been categorized as a level 3 fair value based on the inputs to the valuation techniques used.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

8. Investments in Associates and Joint Ventures

Investments in associates and joint ventures as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won			Se	eptember 30 2017	December 31 2016	
			Percentage	2017	Percentage	
			of	Carrying	of	Carrying
Company	Locatio	n Principal operation	ownership	amount	ownership	amount
Lite Pharm Tech, Inc.	Korea	Manufacturing medical supplies	20.24%	₩ 1,830	20.24%	₩ 1,830
KVG REIT 1 Co., Ltd.	Korea	Renting real estate	-	-	29.67%	7,300
JR REIT V Co., Ltd.	Korea	Renting real estate	34.63%	5,600	34.63%	5,600
JR REIT VIII Co., Ltd.	Korea	Renting real estate	21.74%	10,000	21.74%	10,000
LSK Global	Korea	Researching				
Pharma Services Co., Ltd.		and developing medicine	23.15%	-	23.15%	-
JR REIT X Co., Ltd.	Korea	Renting real estate	28.79%	9,500	28.79%	9,500
JR REIT XIII Co., Ltd.	Korea	Renting real estate	27.03%	5,000	27.03%	5,000
KB Gimpo Logistics						
CR REIT Co., Ltd. (*1)	Korea	Renting real estate	12.00%	3,000	12.00%	3,000
KORAMCO Private REIT 50 Fund	*2)Korea	Renting real estate	84.21%	16,000	84.21%	16,000
Yong-in Jungsim Inc	Korea	Renting real estate	22.22%	1,000		
·				₩ 51,930		₩ 58,230

^(*1) KB Gimpo Logistics CR REIT Co., Ltd is classified as a joint venture since decisions about the significant financial and operating policy of the investee cannot be made without unanimous consent of the parties, holding 12% shares each, as the voting power of 76% shares held by the collective investment business entity is not entitled to have an impact on a resolution of the investee by the *Financial Investment Services and Capital Markets Act*.

In 2017, the Company recognized W19 million of gain on sale of investments in associates and joint ventures as KVG REIT 1 Co, Ltd. was liquidated.

In 2017, the Company made an investment of \(\psi 1,000\) million in Yong-in Jungsim Inc.

In 2016, the Company made an investment of \text{\psi}3,000 million and \text{\psi}16,000 million in KB Gimpo Logistics CR REIT Co., Ltd and KORAMCO Private REIT 50 Fund, respectively.

In 2016, the Company recognized \(\psi_6,095\) million of gain on sale of investments in associates and joint ventures as KOCREF REIT 17 Co., Ltd. was liquidated.

^(*2) KORAMCO Private REIT 50 Fund is classified as a joint venture since decisions about the significant financial and operating policy of the investee cannot be made without unanimous consent of the parties that control the arrangement collectively.

For the nine-month periods ended September 30, 2017 and 2016

9. Investments in Subsidiaries

Investments in subsidiaries as of September 30, 2017 and December 31, 2016 are summarized as follows:

			September 30		December 31	
In millions of won		_		2017		2016
			Percentage		Percentage	
	to a section	District Control of Control	of	Carrying	of	Carrying
Company	Location	Principal operation	ownership	amount	ownership	amount
Korea Ginseng Corporation	Korea	Manufacturing				
		and selling ginseng	100.00% W	716,148	100.00%	₩ 716,148
Yungjin Pharm. Co., Ltd.	Korea	Manufacturing and				
		selling pharmaceutical	52.45%	73,299	53.00%	66,355
Tae-a Industry Co., Ltd.	Korea	Manufacturing				
		tobacco materials	100.00%	15,698	100.00%	15,698
KT&G Tutun Mamulleri	Turkey	Manufacturing				
Sanayi ve Ticaret A.S.		and selling tobaccos	99.99%	30,049	99.99%	30,049
Korea Tabacos do Brasil Ltda.	Brazil	Processing leaf tobaccos	99.99%	2,891	99.99%	2,891
KT&G Pars	Iran	Manufacturing				
		and selling tobaccos	99.99%	-	99.99%	-
KT&G Rus L.L.C.	Russia	Manufacturing				
		and selling tobaccos	100.00%	110,297	100.00%	110,297
KT&G USA Corporation	USA	Selling tobaccos	100.00%	4,913	100.00%	4,913
Cosmocos Co., Ltd.	Korea	Manufacturing				
		and selling cosmetics	98.56%	103,638	98.49%	98,093
Renzoluc Pte., Ltd. (*)	Singapore	Manufacturing				
		and selling tobaccos	100.00%	144,691	100.00%	-
KT&G Life	Korea	Researching and				
Sciences Corporation		developing medicine	-	-	34.03%	15,852
KGC Yebon Corporation	Korea	Manufacturing and				
		selling medical herbs	100.00%	49,828	100.00%	49,828
K-Q HongKong I, Limited	HongKong	Manufacturing				
		and selling ginseng	-	-	100.00%	17,761
PT KT&G Indonesia	Indonesia	Manufacturing				
		and selling tobaccos	99.99%	-	99.99%	-
K&I HK Co., Ltd.	HongKong	Selling cosmetics	-	-	100.00%	11
K&I China Co., Ltd.	China	Selling cosmetics	-	-	100.00%	5,532
SangSang Stay, Inc.	Korea	Hotel	100.00%	20,000	100.00%	20,000
KT&G Global Rus L.L.C.	Russia	Selling tobaccos	100.00%	1,497	100.00%	1,497
				1,272,949		W 1,154,925

The Company's percentage of ownership, shown above, excludes redeemable convertible preferred shares. As of September 30, 2017, the Company's percentage of ownership would be 88.6%, if preferred shares are included.

For the nine-month periods ended September 30, 2017 and 2016

9. Investments in Subsidiaries, Continued

For the nine-month period ended September 30, 2017, the Company invested \(\frac{\pmax}{9}\)7,202 million in cash to acquire additional 25,641,958 shares of Renzoluc Pte and acquired additional 13,151,932 shares of Renzoluc Pte due to conversion of loans.

For the nine-month period ended September 30, 2017, the Company made a capital contribution in-kind to Cosmocos Co., Ltd. by transferring its interest in K&I HK Co., Ltd. and K&I China Co., Ltd., increasing its ownership from 98.49% to 98.56%. The Company measured the additional interest in Cosmocos Co., Ltd. at the carrying amount of its investment in K&I HK Co., Ltd. and K&I China Co., Ltd., considering the transaction did not have a discernible effect on the Company's economics.

KT&G Life Sciences Corporation, a subsidiary of the Company was merged into Yungjin Pharm. Co., Ltd. as of January 13, 2017. For the nine-month period ended September 30, 2017, the Company recognized \(\fomallow\)8,908 million of loss on disposal of investments in subsidiaries to recognize the difference between consideration transferred for fair value of Yungjin Pharm. Co., Ltd.'s shares and book value of interests in KT&G Life Sciences Corporation.

For the nine-month period ended September 30, 2017, the Company recognized \(\psi \)37 million of loss on disposal of investments in subsidiaries as K-Q HongKong I, Limited was liquidated.

For the year ended December 31, 2016, the Company acquired \(\psi_27,417\) million of additional shares of Cosmocos Co., Ltd. as a result of the conversion of its redeemable convertible preferred shares, increasing its ownership from 97.73% to 98.49%.

For the year ended December 31, 2016, redeemable convertible preferred shares of KT&G Life Sciences Corporation were converted and the Company acquired \(\pmu\)1,565 million of additional shares of the investee, decreasing its ownership interest to 34.03% from 73.94%. As of January 13, 2017, KT&G Life Sciences Corporation was merged into Yungjin Pharm. Co., Ltd.

For the year ended December 31, 2016, the Company made a capital contribution in-kind of its interest in KGC Life & Gin Co., Ltd. to Korea Ginseng Corporation and measured the additional interest in Korea Ginseng Corporation at the carrying amount of its investment in KGC Life & Gin Co., Ltd., considering the transaction did not have a discernible effect on the Company's economics.

For the year ended December 31, 2016, the Company established KT&G Global Rus L.L.C.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

10. Available-for-sale Financial Assets

(a) Changes in available-for-sale financial assets for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	365,805	340,149
Acquisitions		52,946	31,000
Net changes in fair value		21,922	28,643
Disposals or reclassification		(5,515)	(33,987)
Ending balance	₩	435,158	365,805
Statement of financial position:			
Current	W	-	1,500
Non-current		435,158	364,305
	₩	435,158	365,805

For the nine-month period ended September 30, 2017, the Company reclassified \(\frac{\pmathbb{W}}{2}\),054 million of investment in the debt security of LSK Global Pharma Services Co., Ltd., whose maturity has been expired, to loans. The Company recognized \(\frac{\pmathbb{W}}{2}\)554 million of gain on sale of available-for-sale financial assets difference between the fair value and the carrying amount of the investment.

For the nine-month period ended September 30, 2017, the Company recognized W460 million of gain on sale of available-for-sale financial assets.

For the nine-month period ended September 30, 2017, the Company recognized \(\psi\)18,167 million of impairment loss on its investment in an equity instrument of U&I Corporation as there was a significant and prolonged decline in the fair value below below its cost.

For the year ended December 31, 2016, the Company recognized \(\fomathbf{W}\)13,988 million of gain on sale of available-for-sale financial assets upon liquidation of Mastern 2 REIT Co., Ltd.

For the year ended December 31, 2016, the Company recognized \(\fomatsum4,077\) million of impairment loss on its investment in an equity instrument of Rexahn Pharmaceuticals, Inc. as there was a significant and prolonged decline in the fair value below its cost.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

10. Available-for-sale Financial Assets, Continued

(b) Available-for-sale financial assets as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	September 30 2017		December 31 2016
Available-for-sale debt instruments: Corporate bonds	₩	-	1,500
Available-for-sale equity instruments: Listed			
- Oscotech, Inc.		3,939	3,775
– Shinhan Financial Group Co., Ltd.		201,620	181,378
– Rexahn Pharmaceuticals, Inc.		1,773	1,081
– U&I Corporation		10,823	14,060
		218,155	200,294
Unlisted		217,003	164,011
Total available-for-sale equity instruments		435,158	364,305
Total available-for-sale financial assets	₩	435,158	365,805

The fair value of listed available-for-sale equity instruments is principally based on quoted prices in an active market.

As of September 30, 2017 and December 31, 2016, \(\precequiv31,055\) million and \(\precequiv32,555\) million of available-for-sale financial assets that do not have a market price in an active market and whose fair value cannot be reliably measured are measured at cost, respectively.

11. Long-term Deposits in MSA Escrow Fund

Long-term deposits in MSA Escrow Fund as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	S	eptember 30 2017	December 31 2016
Demand deposits	₩	2,638	=
MMF		-	56,069
Treasury bill		-	21,559
Treasury note		533,025	425,964
	₩	535,663	503,592

As discussed in note 33 to the separate interim financial statements, long-term deposits in MSA Escrow Fund are deposited to the United States government related to the export of tobacco to the United States. For the nine-month periods ended September 30, 2017 and 2016, W57,338 million and W68,897 million were paid into long-term deposits in MSA Escrow Fund, respectively.

Long-term deposits in MSA Escrow Fund are invested in demand deposits of financial institutions or government and public bonds. Investment income on long-term deposits in MSA Escrow Fund for the nine-month periods ended September 30, 2017 and 2016 are \text{W4,606} million and \text{W3,554} million, respectively.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

12. Trade and Other Receivables

(a) Trade and other receivables as of September 30, 2017 and December 31, 2016 are summarized as follows:

			September 30 2017	December 31 2016	
In millions of won	_	Current	Non-current	Current	Non-current
Loans to employees	₩	15,690	30,264	16,687	38,853
Loans		6,451	4,858	55,644	4,230
Other receivables		33,327	7,059	104,677	4,568
Guarantee deposits		28,561	15,496	22,121	20,366
Accrued income		8,565	-	10,384	-
Trade receivables		1,185,498	-	931,085	-
	₩	1,278,092	57,677	1,140,598	68,017

(b) Trade and other receivables as of September 30, 2017 and December 31, 2016 have been reported in the separate statements of financial position net of allowances as follows:

			September 30 2017		December 31 2016
In millions of won		Current	Non-current	Current	Non-current
Gross trade and other receivables Allowance:	₩	1,333,404	77,567	1,200,737	79,643
Loans		(13,287)	(19,890)	(24,194)	(11,626)
Other receivables		(11,739)	-	(11,459)	-
Accrued income		(2,217)	-	(2,333)	-
Trade receivables		(28,069)	-	(22,153)	-
		(55,312)	(19,890)	(60,139)	(11,626)
Net trade and other receivables	₩	1,278,092	57,677	1,140,598	68,017

(c) Changes in the allowance account for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	71,765	46,186
Impairment loss		5,923	27,331
Reversal of impairment loss		(2,486)	(1,752)
Ending balance	₩	75,202	71,765

Impairment loss (reversal of impairment loss) on trade and other receivables is included as part of selling, general and administrative expenses and other expense (income) in the separate statements of comprehensive income.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

12. Trade and Other Receivables, Continued

(d) The aging schedule of trade and other receivables which were past due but not impaired as of September 30, 2017 and December 31, 2016 is as follows:

	S	eptember 30	December 31
In millions of won		2017	2016
Within 1 month	₩	53,747	43,957
Between 1 and 2 months		48,521	52,048
Beyond 2 months		230,715	257,877
	₩	332,983	353,882

There is no significant concentration of credit risk with respect to trade and other receivables since trade and other receivables, excluding export trade receivables, are widely dispersed amongst a number of customers. The Company holds pledged assets and guarantees in respect of some of the past due debtor balances.

(e) Details of trade and other receivables that are measured at amortized cost as of September 30, 2017 and December 31, 2016 were as follows:

			September 30 2017			December 31 2016
	Effective			Effective		
In millions of won	interest rate	Current	Non-current	interest rate	Current	Non-current
Loans to employees	1.89~5.68%	15,690	30,264	1.89~5.68% W	16,687	38,853
Guarantee deposits	1.78~5.68%	28,561	15,496	1.78~5.68%	22,121	20,366
		44,251	45,760	₩	38,808	59,219

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

13. Inventories

(a) Inventories as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	5	September 30 2017	December 31 2016
Finished goods, net of loss on write-down of inventories	₩	63,658	69,414
Work-in-progress		16,834	17,167
Raw materials		627,704	724,281
Supplies		26,148	28,429
By-products		5,335	6,041
Buildings under construction		-	699
Sites for lotting-out construction		3,687	12,985
Goods-in-transit		12,874	55,686
	₩	756,240	914,702

(b) The amount of inventories recognized as an expense for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Cost of sales:					
Write-down (reversal of write-down) of inventories	₩	497	838	133	178
Loss on retirement of inventories		244	1,598	1,044	1,852
Other expense:					
Loss on retirement of inventories		26	71	16	235
	₩	767	2,507	1,193	2,265

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

14. Cash and Cash Equivalents and Other Financial Assets

(a) Cash and cash equivalents as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	September 30 2017	December 31 2016
Cash on hand	₩ 1,052	1,095
Demand deposits	82,309	77,640
Short-term investment assets	1,060,000	610,000
	₩ 1,143,361	688,735

(b) Other financial assets as of September 30, 2017 and December 31, 2016 are summarized as follows:

			December 31		
			2017		2016
In millions of won		Current	Non-current	Current	Non-current
Time deposits	₩	100,000	6,340	100,000	-
Money trust		1,120,000	-	1,480,000	-
Certificates of deposit		40,000	-	40,000	=
	₩	1,260,000	6,340	1,620,000	-

In 2015, the Company acquired redeemable convertible preference shares of Cosmocos Co., Ltd. and recognized embedded derivatives as other financial assets separately from the host contract. The Company exercised those conversion options and recognized \(\pi \)311 million of gain on conversion of redeemable convertible preferred shares for the year ended December 31, 2016.

(c) Financial assets restricted in use as of September 30, 2017 were as follows:

In millions of won		2017
Other financial assets	₩	6,340

15. Non-current Assets Held for Sale

Changes in non-current assets held for sale for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	-	1,542
Disposal		-	(1,542)
Ending balance	₩	-	-

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

16. Pledged Assets

(a) Investment property pledged as collateral as of September 30, 2017 was as follows:

In millions of won	Carrying		Received	Collateralized	
Asset	amount	Туре	amount	amount	Secured party
Investment property 4	№ 149,892	Leasehold deposits received	12,982	13,889	MetLife Insurance Korea Co., Ltd. and others
Other financial assets	6,340	Performance guarantee	-	6,340	Korea Land and Housing Corporation

(b) Investment property pledged as collateral as of December 31, 2016 was as follows:

In millions of won

		Carrying			Received	Collateralized	
Asset		amount	Type		amount	amount	Leaseholder
Investment property	₩	68,810	Leasehold deposits received	₩	9,241	9,467	MetLife Insurance Korea Co., Ltd. and others

17. Share Capital and Other Capital Surplus

(a) Details of share capital as of September 30, 2017 and December 31, 2016 were as follows:

	September 30	December 31	
	2017	2016	
Number of ordinary shares:			
Authorized	800,000,000	800,000,000	
Issued	137,292,497	137,292,497	
Outstanding	126,265,127	126,265,127	
Par value in won	₩ 5,000	5,000	

The Company has 53,699,400 shares of treasury shares reacquired and retired in prior years. Accordingly, as of September 30, 2017, the Company's ordinary share differs from the aggregate par value of issued shares by \$\fomathbf{W}\$268,497 million.

(b) Changes in the number of shares for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

			2017			2016
	Ordinary	Treasury		Ordinary	Treasury	
Number of share	shares	shares	Total	shares	shares	Total
Beginning balance	137,292,497	(11,027,370)	126,265,127	137,292,497	(11,326,605)	125,965,892
Donation of treasury shares	-	-	-	-	299,235	299,235
Ending balance	137,292,497	(11,027,370)	126,265,127	137,292,497	(11,027,370)	126,265,127

(c) There was no change in other capital surplus for the nine-month period ended September 30, 2017 and the year ended December 31, 2016.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

18. Treasury Shares and Gain on Reissuance of Treasury shares

(a) Changes in treasury shares for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

		2017		2016
	Number	Carrying	Number	Carrying
In millions of won, except number of shares	of shares	amount	of shares	amount
Beginning balance	11,027,370	₩ 328,157	11,326,605	₩ 337,062
Donation of treasury shares	=	-	(299,235)	(8,905)
Ending balance	11,027,370	₩ 328,157	11,027,370	₩ 328,157

(b) Changes in gain on reissuance of treasury shares for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	513,776	494,648
Donation of treasury shares, net of tax		-	19,128
Ending balance	₩	513,776	513,776

19. Reserves

(a) Details of reserves as of September 30, 2017 and December 31, 2016 were as follows:

In millions of won		September 30 2017	December 31 2016
Available-for-sale financial assets - net change in fair value	₩	(1,311)	(30,929)
Legal reserve		602,937	602,937
Voluntary reserve		4,408,176	3,794,260
	₩	5,009,802	4,366,268

(b) Available-for-sale financial assets - net change in fair value as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	Se	eptember 30 2017	December 31 2016
Available-for-sale financial assets - net change in fair value before tax Tax effect	₩	(1,729) 418	(40,804) 9.875
TAX GITGGE	₩	(1,311)	(30,929)

(c) Legal Reserve

The Korean Commercial Act requires the Company to appropriate a legal reserve in an amount equal to at least 10% of cash dividends for each accounting period until the reserve equals 50% of stated capital. The legal reserve may be used to reduce a deficit or may be transferred to ordinary shares in connection with a free issue of shares.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

19. Reserves, Continued

(d) Details of voluntary reserve as of September 30, 2017 and December 31, 2016 were as follows:

In millions of won		September 30 2017	December 31 2016
Reserve for business rationalization	₩	12,851	12,851
Reserve for research and human resource development		10,000	20,000
Reserve for business expansion		698,881	698,881
Unconditional reserve		3,686,444	3,062,528
	₩	4,408,176	3,794,260

Reserve for business rationalization

Until December 10, 2002 under the Restriction of Special Taxation Act, investment tax credits were allowed for certain investments. The Company was, however, required to appropriate from retained earnings, the amount of tax benefits received, and transfer such amount into a reserve for business rationalization.

Effective December 11, 2002, the Company was no longer required to establish a reserve for business rationalization despite tax benefits received for certain investments and, consequently, the existing balance is now regarded as a voluntary reserve.

Reserve for research and human resource development

According to the Restriction of Special Taxation Act, certain taxable deductions are required to be transferred from retained earnings to reserve for research and human resource development. This reserve may be used for each purpose and their remaining amounts could be reclassified as a voluntary reserve.

Reserve for business expansion and other reserves

The Company appropriated reserves without specific purposes. Those reserves can be used for other purposes upon a resolution at a general meeting of shareholders.

20. Retained Earnings

Changes in retained earnings for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	1,068,469	995,886
Dividends		(454,554)	(428,284)
Transfer from reserve for research and human resource development		10,000	10,000
Transfer to unconditional reserve		(623,915)	(577,602)
Profit for the period		786,072	1,087,347
Remeasurements of net defined benefit liability, net of tax		(358)	(18,878)
Ending balance	₩	785,714	1,068,469

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

21. Trade and Other Payables

Trade and other payables as of September 30, 2017 and December 31, 2016 are summarized as follows:

			September 30 2017		December 31 2016
In millions of won		Current	Non-current	Current	Non-current
Leasehold deposits received	₩	21,467	12,362	21,418	6,848
Trade payables		18,596	-	67,961	-
Withholdings		4,004	-	3,802	-
Withholdings value added tax		198,457	-	186,347	-
Accrued expenses		121,709	-	123,401	-
Other payables		28,518	-	33,341	-
	₩	392,751	12,362	436,270	6,848

22. Short-term Borrowings

Short-term borrowings as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	Annual interest rate		September 30 2017	December 31 2016
Customer credit contracts:				
Nonghyup Bank	5.92%	₩	2,355	3,179
KEB Hana Card Co., Ltd.	3M CD rate+2.5%		435	672
		₩	2,790	3,851

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

23. Retirement Benefits Plan

(a) The components of retirement benefits for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Defined benefit plans:					
Current service cost	₩	6,674	20,022	6,225	18,674
Net interest cost		236	707	232	696
		6,910	20,729	6,457	19,370
Defined contribution plans:					
Contributions recognized as expense		1,945	5,294	1,647	4,236
	₩	8,855	26,023	8,104	23,606

(b) Net defined benefit liability as of September 30, 2017 and December 31, 2016 is summarized as follows:

In millions of won	September 30 2017	
Present value of defined benefit obligations	₩ 293,996	/ -
Fair value of plan assets	(226,672	2) (231,491)
Net defined benefit liability	₩ 67,324	47,121

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

24. Revenue from Real Estate Sales

(a) Details of agreements for real estate sales under construction as of September 30, 2017 were as follows:

			Total	Total
			revenue	revenue
In millions of won	Construction period		estimated	contracted
Daegu Station Central-Xi	Dec. 2014 ~ Oct. 2017	₩	343,950	343,950

(b) Changes in the balance of contract amount for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	133,491	246,340
Other changes		1,725	23,700
Revenue recognized		(99,164)	(136,549)
Ending balance	₩	36,052	133,491

(c) Recognized profits and related balances for agreements under construction as of September 30, 2017 were as follows:

			Aggregate	Aggregate	Due from
	Stage of		revenue	expenses	customers for
In millions of won	completion		recognized	recognized	contract work
Daegu Station Central-Xi	89.52%	₩	307,898	246,728	72,993

Due from customers for contract work is recognized as trade and other receivables in the separate interim financial statements.

(d) There was no change in the estimates of total revenue and total costs during the nine-month period ended September 30, 2017. The total revenue and the total costs are estimated based on the information and circumstances available at the end of the reporting period and actual results may differ from these estimates.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

25. Result from Operating Activities

(a) Details of expenses classified by nature for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Changes in inventories	₩	51,566	158,461	25,470	64,981
Raw materials and consumables purchased		187,459	482,799	158,987	517,425
Salaries		96,200	263,480	85,574	250,881
Retirement and termination benefits		8,855	26,023	8,104	23,606
Depreciation		25,661	77,350	26,600	78,644
Amortization		13	28	5	15
Employee welfare		11,996	34,025	12,189	34,298
Advertising		27,119	75,592	28,159	78,483
Commissions		31,444	90,913	26,954	80,171
Other expenses		10,705	106,614	32,501	72,675
	₩	451,018	1,315,285	404,543	1,201,179

(b) Details of selling, general and administrative expenses for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Salaries	₩	64,395	177,031	57,480	169,231
Retirement and termination benefits		6,153	18,201	5,568	16,403
Employee welfare		8,634	24,266	8,965	25,000
Travel		2,570	6,428	1,822	4,464
Communications		786	2,283	812	2,520
Utilities		2,397	6,635	2,168	6,317
Taxes and dues		1,167	16,332	1,884	15,461
Supplies		406	1,335	302	1,097
Rent		3,336	9,534	3,520	9,848
Depreciation		8,264	25,006	7,941	23,958
Amortization		13	28	5	15
Repairs and maintenance		1,302	2,998	730	2,318
Vehicles		1,026	3,032	1,058	3,041
Insurance		89	348	58	235
Commissions		23,635	66,903	19,899	58,090
Freight and custody		7,456	21,298	5,584	17,596
Conferences		732	2,354	616	2,014
Advertising		27,092	75,486	28,129	78,373
Training		897	2,506	834	2,622
Prizes and rewards		438	1,207	301	904
Normal research and development		3,943	10,673	2,497	7,178
Impairment loss on trade receivables		2,894	5,916	7	3
	₩	167,625	479,800	150,180	446,688

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

26. Other Income and Expenses

(a) Details of other income for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Foreign currency transaction gain	₩	1,182	6,577	1,766	12,841
Foreign currency translation gain		14,253	7,755	-	114
Reversal of impairment loss on other receivables		474	2,486	-	-
Gain on sale of property, plant and equipment		479	4,641	350	11,903
Gain on sale of intangible assets		-	595	-	-
Gain on sale of investments in associates		19	19	-	6,095
Others		4,469	12,485	4,842	13,430
	₩	20,876	34,558	6,958	44,383

(b) Details of other expenses for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Foreign currency transaction loss	₩	7,830	37,791	11,701	21,656
Foreign currency translation loss		-	31,883	53,354	60,441
Impairment loss on other receivables		7	7	64	583
Donations		1,966	5,004	20,579	23,781
Loss on disposal of subsidiaries		-	8,945	_	-
Loss on sale of property, plant and equipment		185	320	26	897
Loss on sale of intangible assets		2,574	3,121	3	8
Others		42	5,134	4,122	5,621
	₩	12,604	92,205	89,849	112,987

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

27. Net Finance Income

(a) Details of net finance income for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Finance income:					
Interest income	₩	9,414	29,464	8,514	26,948
Dividend income		4,156	82,549	1,895	13,322
Interest income on					
long-term deposits in MSA Escrow Fund		540	4,606	(535)	3,554
Gain on sale of available-for-sale financial assets		-	1,014	-	-
Gain on conversion of					
redeemable convertible preferred shares		-	-	=	311
		14,110	117,633	9,874	44,135
Finance costs:					
Interest expense		(211)	(739)	(157)	(503)
Impairment loss on					
available-for-sale financial assets		(3,528)	(18,167)	-	-
		(3,739)	(18,906)	(157)	(503)
Net finance income	₩	10,371	98,727	9,717	43,632

(b) Details of interest income for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

		2017		2016
In millions of won	Three-month	Nine-month	Three-month	Nine-month
Deposits \	9,002	26,479	6,533	20,629
Available-for-sale financial assets	-	/	8	22
Trade and other receivables	412	2,978	1,973	6,297
<u></u>	9,414	29,464	8,514	26,948

(c) Details of interest expenses for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Trade and other payables	₩	211	739	157	503

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

28. Income Tax

Income tax expense comprises as current tax expense adjusted for current adjustments for prior periods, deferred tax expense (income) by origination and reversal of deferred tax assets (liabilities), and income tax recognized in other comprehensive income. The average effective tax rate was 24.60% and 24.26% for the nine-month periods ended September 30, 2017 and 2016, respectively.

29. Earnings per Share

Basic and diluted earnings per share for the three- and nine-month periods ended September 30, 2017 and 2016 were as follows:

			2017		2016
		Three-month	Nine-month	Three-month	Nine-month
Profit for the period in millions of won Weighted-average number	₩	269,471	786,072	207,988	738,004
of ordinary shares outstanding		126,265,127	126,265,127	126,143,670	126,137,182
Basic and diluted earnings per share in won	₩	2,134	6,226	1,649	5,851

The weighted-average number of ordinary shares outstanding is the number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

30. Transactions and Balances with Related Parties

(a) Details of parent and subsidiary relationships and related companies as of September 30, 2017 and December 31, 2016 were as follows:

		Percentage of ownership					ship
			Septe	ember 30		mber 31	
0.1.15	100		0.1.11	2017		0.1.11	2016
Subsidiary	Location	Parent	Subsidiary	Total	Parent	Subsidiary	Total
Investments in subsidiaries							
Korea Ginseng Corporation	Korea	100.00%	-	100.00%	100.00%	-	100.00%
Yungjin Pharm. Co., Ltd. (*1)	Korea	52.45%	-	52.45%	53.00%	-	53.00%
Tae-a Industry Co., Ltd.	Korea	100.00%	-	100.00%	100.00%	-	100.00%
KT&G Tutun Mamulleri Sanayi ve Ticaret A.S.	Turkey	99.99%	-	99.99%	99.99%	-	99.99%
Korea Tabacos do Brasil Ltda.	Brazil	99.99%	-	99.99%	99.99%	-	99.99%
KT&G Pars	Iran	99.99%	-	99.99%	99.99%	-	99.99%
KT&G Rus L.L.C.	Russia	100.00%	-	100.00%	100.00%	-	100.00%
KT&G USA Corporation	USA	100.00%	-	100.00%	100.00%	-	100.00%
Cosmocos Co., Ltd. (*2,3)	Korea	98.56%	-	98.56%	98.49%	-	98.49%
Renzoluc Pte., Ltd.(*4)	Singapore	100.00%	-	100.00%	100.00%	-	100.00%
KT&G Life Sciences Corporation(*1,5)	Korea	-	-	-	34.03%	-	34.03%
KGC Yebon Corporation	Korea	100.00%	-	100.00%	100.00%	-	100.00%
K-Q HongKong I, Limited ^(*6)	HongKong	-	-	-	100.00%	-	100.00%
PT KT&G Indonesia	Indonesia	99.99%	-	99.99%	99.99%	-	99.99%
K&I HK Co., Ltd. (*3)	HongKong	-	100.00%	100.00%	100.00%	-	100.00%
K&I China Co., Ltd. (*3)	China	-	100.00%	100.00%	100.00%	-	100.00%
SangSang Stay, Inc.	Korea	100.00%	-	100.00%	100.00%	-	100.00%
KT&G Global Rus L.L.C.(*7)	Russia	100.00%	<u>-</u>	100.00%	100.00%	<u>-</u>	100.00%
KGC Life & Gin Co., Ltd. (*8)	Korea	-	100.00%	100.00%	-		100.00%
Jilin Hanzheng Ginseng Co., Ltd.	China	-	100.00%	100.00%	-	100.00%	100.00%
Cheong Kwan Jang Taiwan Corporation	Taiwan	-	100.00%	100.00%	-	100.00%	100.00%
Korean Red Ginseng Corp., Inc.	USA	-	100.00%	100.00%	-	100.00%	100.00%
Korea Ginseng (China) Corp.	China	-	100.00%	100.00%	-		100.00%
Korea Ginseng Corporation Japan	Japan	-	100.00%	100.00%	-	.00.0070	100.00%
PT CKJ INDONESIA	Indonesia	-	99.88%	99.88%	-		99.88%
PT Trisakti Purwosari Makmur (*9)	Indonesia	-	99.99%	99.99%	-	00.1770	60.17%
PT Mandiri Maha Mulia (*9)	Indonesia	-	99.98%	99.98%	-	00.1770	66.47%
PT Sentosa Ababi Purwosari (*9)	Indonesia	-	100.00%	100.00%	-	99.80%	99.80%
PT Purindo Ilufa (*9)	Indonesia	-	100.00%	100.00%	-	100.00%	100.00%
PT Nusantara Indah Makmur (*9)	Indonesia	-	100.00%	100.00%	-	-	-
Investments in associates and joint ventures							
Lite Pharm Tech, Inc.	Korea	20.24%	_	20.24%	20.24%	_	20.24%
KVG REIT 1 Co., Ltd. (*10)	Korea	20.2470	_	20.2470	29.67%	_	29.67%
JR REIT V Co., Ltd.	Korea	34.63%	_	34.63%	34.63%	_	34.63%
JR REIT VIII Co., Ltd.	Korea	21.74%	_	21.74%	21.74%	_	21.74%
LSK Global Pharma Services Co., Ltd.	Korea	23.15%	_	23.15%	23.15%	_	23.15%
JR REIT X Co., Ltd.	Korea	28.79%	_	28.79%	28.79%	_	28.79%
JR REIT XIII Co., Ltd.	Korea	27.03%	_	27.03%	27.03%	_	27.03%
KB Gimpo Logistics CR REIT Co., Ltd.	Korea	12.00%	_	12.00%	12.00%	_	12.00%
KORAMCO Private REIT 50 Fund	Korea	84.21%	_	84.21%	84.21%	_	84.21%
Yong-in Jungsim Inc.*11)	Korea	22.22%	_	22.22%		_	
Tong in oungoin ino.	Norou	22.22 /0		~~.~~ /U			

^(*1) KT&G Life Sciences Corporation was merged into Yungjin Pharm. Co., Ltd. as of January 13, 2017.

The ownership interest in Cosmocos Co., Ltd. has increased to 98.49% from 97.73% as a result of the conversion of redeemable convertible preferred shares in 2016.

For the nine-month period ended September 30, 2017, the Company made a capital contribution in-kind to Cosmocos Co., Ltd. by transferring its interest in K&I HK Co., Ltd. and K&I China Co., Ltd., increasing its ownership from 98.49% to 98.56%.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

30. Transactions and Balances with Related Parties, Continued

- (a) Details of parent and subsidiary relationships and related companies as of September 30, 2017 and December 31, 2016 were as follows, Continued:
 - The percentage of ownership, shown above, excludes preferred shares. As of September 30, 2017, the Company's percentage of ownership would be 88.6%, if preferred shares are included.
 - The ownership interest in KT&G Life Sciences Corporation has decreased to 34.03% from 73.94% as a result of the conversion of redeemable convertible preferred shares in 2016.
 - (*6) For the nine-month period ended September 30, 2017, K-Q HongKong I, Limited was liquidated.
 - (*7) The Company established KT&G Global Rus L.L.C in 2016.
 - (*8) The Company made a capital contribution in-kind of its entire interest in KGC Life & Gin Co., Ltd. to Korea Ginseng Corporation in 2016.
 - For the nine-month period ended September 30, 2017, PT Trisakti Purwosari Makmur, a subsidiary, acquired PT Nusantara Indah Makmur.
 - (*10) For the nine-month period ended September 30, 2017, KVG REIT 1 Co, Ltd. was liquidated
 - For the nine-month period ended September 30, 2017, the Company acquired a 22.22% shares in Yong-in Jungsim Inc.
- (b) Significant transactions which occurred in the normal course of business with related companies for the threeand nine-month periods ended September 30, 2017 and 2016 are summarized as follows:

(i) Sales and other income

			2017		2017
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Korea Ginseng Corporation	₩	1,925	5,615	1,944	5,808
Yungjin Pharm. Co., Ltd.		36	122	69	239
Tae-a Industry Co., Ltd.		4	8	3	10
KT&G Tutun Mamulleri Sanayi ve Ticaret A.S.		1,944	6,037	375	1,086
KT&G Pars		1,499	2,101	-	323
KT&G Rus L.L.C.		7,433	19,073	3,189	18,541
KGC Life & Gin Co., Ltd.		27	92	90	297
KT&G USA Corporation.		20,071	72,512	28,173	92,645
Cosmocos Co., Ltd.		26	80	27	121
Renzoluc Pte., Ltd.		-	763	1,017	2,949
KT&G Life Sciences Corporation		-	-	4	15
KGC Yebon Corporation		6	18	-	96
PT KT&G Indonesia		320	798	374	1,207
K&I China Co., Ltd.		-	-	208	209
SangSang Stay, Inc.		1,644	4,936	1,443	2,201
PT Trisakti Purwosari Makmur		-	-	54	142
PT Mandiri Maha mulia		4,240	10,491	1,719	3,648
	₩	39,175	122,646	38,689	129,537

In addition, the Company disposed of property, plant and equipment with a carrying amount of \(\psi_5,711\) million and \(\psi_3,205\) million to KT&G Rus L.L.C and PT Mandiri Maha mulia, respectively, during the nine-month period ended September 30, 2017.

In addition, the Company disposed of property, plant and equipment with a carrying amount of \text{W4,920} million and \text{W3,391} million to SangSang Stay, Inc. and PT Mandiri Maha mulia, respectively, during the nine-month period ended September 30, 2016.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

30. Transactions and Balances with Related Parties, Continued

(b) Significant transactions which occurred in the normal course of business with related companies for the threeand nine-month periods ended September 30, 2017 and 2016 are summarized as follows, Continued:

(ii) Purchase and other expenses

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Korea Ginseng Corporation	₩	395	2,063	910	2,398
Yungjin Pharm. Co., Ltd.		26	33	3	11
Tae-a Industry Co., Ltd.		3,603	10,401	3,091	10,630
KT&G Rus L.L.C.		86	421	-	-
KGC Life & Gin Co., Ltd.		-	183	4	253
Cosmocos Co., Ltd.		34	95	10	417
KGC Yebon Corporation		-	-	-	260
K&I China Co., Ltd.		-	23	13	59
SangSang Stay, Inc.		-	-	-	33
	₩	4,144	13,219	4,031	14,061

(c) Account balances with related companies as of September 30, 2017 and December 31, 2016 were as follows:

			September 30 2017		December 31 2016
In millions of won	_	Receivables	Payables	Receivables	Payables
Investments in subsidiaries					
Korea Ginseng Corporation	₩	-	913	37	2,071
Yungjin Pharm. Co., Ltd.		6	30	13	30
KT&G Tutun Mamulleri Sanayi ve Ticaret A.S.		38,325	-	38,159	-
Korea Tabacos do Brasil Ltda.		102	-	101	-
KT&G Pars ^(*)		46,454	-	43,385	-
KT&G Rus L.L.C. (*)		59,569	-	58,652	-
KT&G USA Corporation		20,998	-	19,015	-
Cosmocos Co., Ltd.		6	115	-	27
Renzoluc Pte., Ltd.		-	-	50,923	-
KT&G Life Sciences Corporation		-	22	-	1
PT KT&G Indonesia		28,946	-	31,185	-
K&I China Co., Ltd.		293	-	1,074	-
SangSang Stay, Inc.		-	-	552	-
KGC Life & Gin Co., Ltd.		-	30	-	115
PT Trisakti Purwosari Makmur		328	-	353	-
PT Mandiri Maha Mulia		15,103	-	11,050	-
Investments in associates and joint ventures					
LSK Global Pharma Services Co., Ltd.		1,854	-	1,508	
	₩	204,872	2,285	256,007	2,244

Above receivables are the gross amounts before \(\psi \)52,909 million and \(\psi \)49,965 million of allowance for doubtful accounts as of September 30, 2017 and December 31, 2016, respectively.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

30. Transactions and Balances with Related Parties, Continued

(d) Details of financial transactions with related parties for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

			2017	2016
	Capital		Loans	Capital
In millions of won	Increase	Increase	Collection	Increase
Investments in subsidiaries				
Korea Ginseng Corporation	-	-	-	44,100
Yungjin Pharm. Co., Ltd.	6,944	-	-	-
Cosmocos Co., Ltd.	5,544	-	-	27,417
Renzoluc Pte., Ltd.	144,691	-	47,490	-
KT&G Life Sciences Corporation	-	-	-	1,564
KT&G Global Rus L.L.C.	-	-	-	1,497
Investments in associates and joint ventures				
LSK Global Pharma Services Co., Ltd.	-	2,054	200	_
Yong-in Jungsim Inc.	1,000	-	-	

KT&G Life Sciences Corporation was merged into Yungjin Pharm. Co., Ltd. as of January 13, 2017.

For the nine-month period ended September 30, 2017, the Company invested \$\footnote{\psi}97,202\$ million in cash to acquire additional 25,641,958 shares of Renzoluc Pte and acquired additional 13,151,932 shares of Renzoluc Pte due to conversion of loans.

For the nine-month period ended September 30, 2017, the Company acquired W5,544 million of additional interest in Cosmocos Co., Ltd. through a capital contribution in-kind of its interest in K&I HK Co., Ltd. and K&I China Co., Ltd.

During the year ended December 31, 2016, the Company acquired W44,100 million of additional shares of Korea Ginseng Corporation through a capital contribution in-kind of its entire investment in KGC Life & Gin Co., Ltd.

During the year ended December 31, 2016, the Company acquired W27,417 million of additional shares of Cosmocos Co., Ltd. as a result of the conversion of its redeemable convertible preferred shares.

(e) Details of key management personnel compensation for the three- and nine-month periods ended September 30, 2017 and 2016 are summarized as follows:

			2017		2016
In millions of won		Three-month	Nine-month	Three-month	Nine-month
Short-term employee benefits Retirement benefits	₩	4,695 156	14,354 1,235	3,762 455	11,317 1,263
	₩	4,851	15,589	4,217	12,580

KT&G CORPORATION Notes to the Separate Interim Financial Statements (Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments

(a) Overview

The Company has exposure to the following risks from its use of financial instruments:

- Market risk
- Credit risk
- Liquidity risk

This note presents information about the Company's exposure to each of the above risks, the Company's objectives, policies and processes for measuring and managing risk including quantitative disclosures.

(b) Risk Management Framework

The purpose of managing financial risks is to identify the potential risk factors that may affect the Company's financial performance, and minimize, eliminate and avoid it to the extent that is acceptable. One of the principal responsibilities of the treasury department is to manage the financial risks arising from the Company's underlying operations. The treasury department monitors and manages the financial risk arising from the Company's underlying operations in accordance with the risk management policies and procedures authorized by the board of directors. Also, the treasury department provides an internal report analyzing the nature and exposure level of financial risks to Risk Management Committee of the Company. The Risk Management Committee prepares the overall strategy for financial risk management, and evaluates the effectiveness of the financial risk management strategy. In addition, the Company's audit committee consistently observes the compliance of the risk management policy and procedure, and reviews the risk exposure limit of the Company. The Company applied the same financial risk management strategy that was applied in the previous period.

(c) Management of Financial Risks

(i) Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

- (c) Management of Financial Risks, Continued
- (i) Market risk, Continued

Currency risk

The Company has exposure to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates arising from the export and import of tobacco. The Company's management has measured the currency risk internally and regularly, and has entered into foreign currency forward contracts to hedge foreign currency risk, if necessary.

The carrying amounts of monetary assets and liabilities denominated in a currency other than the functional currency as of September 30, 2017 and December 31, 2016 were as follows:

			September 30 2017		December 31 2016
In millions of won		Assets	Liabilities	Assets	Liabilities
USD	₩	1,101,528	4,431	1,085,906	52,680
IDR		-	-	51,593	-
EUR		34,627	2,144	29,630	3,023
Others		25,697	-	11,213	-
	₩	1,161,852	6,575	1,178,342	55,703

As of September 30, 2017 and December 31, 2016, the effects of a 10% weakening or strengthening of functional currency against foreign currencies on profit before tax were as follows:

			September 30		December 31
			2017		2016
		10%	10%	10%	10%
In millions of won		weakening	strengthening	weakening	strengthening
Increase (decrease) in profit before tax	₩	115,528	(115,528)	112,264	(112,264)

Equity price risk

The Company has exposure to equity price risk, which arises from listed available-for-sale equity instruments. The Company's management has monitored the proportion of equity instruments in its investment portfolio based on market indices. Material investments within the portfolio are managed on an individual basis, and all buy and sell decisions are approved by the Company's management.

As of September 30, 2017 and December 31, 2016, the effects of a 5% fluctuation in the price index of stocks on comprehensive income before tax were as follows:

			September 30		December 31
			2017		2016
		5%	5%	5%	5%
In millions of won		increase	decrease	increase	decrease
Comprehensive income before tax	₩	8,907	(8,907)	5,162	(5,162)

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

- (c) Management of Financial Risks, Continued
- (i) Market risk, Continued

Interest rate risk

The Company has exposure to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's management has monitored the level of interest rates regularly and has maintained the balance of borrowings at variable rates and fixed rates. As of September 30, 2017, there is no significant effect on cash flows or the fair value of financial liabilities from the interest rate fluctuation, considering the amounts of interest bearing liabilities.

(ii) Credit risk

The Company has exposure to the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company has transacted with customers with high credit ratings to manage credit risk, and has implemented and operated policies and procedures for credit enhancements of the financial assets. Counterparty credit risk is managed by evaluating its credit rating and limiting the aggregate amount and duration of exposure before sales commence, and the Company has been provided collateral and guarantees. The credit ratings of all counterparties and the level of collateral and guarantees are reviewed regularly. Analysis of financial assets past due has been reported quarterly and appropriate measures have been taken to secure the Company's assets.

The carrying amount of financial assets is maximum exposure to credit risk. The maximum exposure to credit risk as of September 30, 2017 and December 31, 2016 is as follows:

In millions of won		September 30 2017	December 31 2016
Available-for-sale debt instruments	₩	-	1,500
Long-term deposits in MSA Escrow Fund		535,663	503,592
Trade and other receivables		1,335,768	1,208,615
Other financial assets		1,266,339	1,620,000
Cash and cash equivalents (excluding cash on hand)		1,142,309	687,640
Financial guarantee contracts		233,379	153,145
	₩	4,513,458	4,174,492

KT&G CORPORATION Notes to the Separate Interim Financial Statements (Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

- (c) Management of Financial Risks, Continued
- (iii) Liquidity risk

The Company has exposure to the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company's management has established short-term and long-term financial management plans to manage the liquidity risk, and analyzed cash outflows occurred and cash outflows budgeted, so as to match the maturity structure of financial assets and financial liabilities. The Company's management determines whether or not the financial liabilities are repayable with the operating cash flows and cash inflows from financial assets.

The contractual maturity analysis with a residual contractual maturity of financial liabilities as of September 30, 2017 and December 31, 2016 is as follows:

					Residual contra	ctual maturity
		0		VA Citta	Between	Between
In millions of won		Carrying amount	Contractual cash flow	Within 3 months	3 months and 1 year	1 and 5 years
		arriourit	Casti flow	3 1110111113	and i year	years
As of September 30, 2017:						
Trade and other payables	₩	202,652	203,590	168,823	21,707	13,060
Short-term borrowings		2,790	2,790	2,790	-	-
Financial guarantee contracts		-	233,379	233,379	-	-
	₩	205,442	439,759	404,992	21,707	13,060
As of December 31, 2016:						
Trade and other payables	₩	252,969	253,467	224,703	21,584	7,180
Short-term borrowings		3,851	3,851	3,851	-	-
Financial guarantee contracts		-	153,145	-	153,145	-
	₩	256,820	410,463	228,554	174,729	7,180

The above financial liabilities are presented at the nominal value of undiscounted future cash flows as of the earliest period at which the Company can be required to pay.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

(d) Fair Value of Financial Instruments

The carrying amounts of each category of financial assets and liabilities as of September 30, 2017 and December 31, 2016 are summarized as follows:

In millions of won	September 30 ns of won 2017		December 31 2016	
Financial assets:				
Available-for-sale financial assets	₩	435,158	365,805	
Loans and receivables				
-Trade and other receivables		1,335,769	1,208,615	
-Long-term deposits in MSA Escrow Fund		535,663	503,592	
–Other financial assets		1,266,340	1,620,000	
–Cash and cash equivalents		1,143,361	688,735	
		4,281,133	4,020,942	
	₩	4,716,291	4,386,747	
Financial liabilities:				
Financial liabilities measured at amortized cost				
-Trade and other payables	₩	202,652	252,969	
-Short-term borrowings		2,790	3,851	
	₩	205,442	256,820	

The fair value measurements classified by fair value hierarchy as of September 30, 2017 and December 31, 2016 were as follows:

		Carrying			Fair value
In millions of won		amount	Level I	Level II	Level III
As of September 30, 2017:					
Available-for-sale financial assets	₩	404,103	218,155	-	185,948
As of December 31, 2016:					
Available-for-sale financial assets	₩	333,250	200,294	-	132,956

There is no transfer between fair value hierarchy levels of recurring fair value measurements for the nine-month period ended September 30, 2017 and the year ended December 31, 2016.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

(d) Fair Value of Financial Instruments, Continued

The fair value measurements for available-for-sale equity instruments in real estate trust fund has been measured using the adjusted net asset method, DCF and option pricing model and categorized as a level 3 fair value based on the inputs to the valuation techniques used. Changes in fair value classified as level 3 for the nine-month period ended September 30, 2017 and the year ended December 31, 2016 were as follows:

In millions of won		2017	2016
Beginning balance	₩	132,956	127,084
Acquisition		52,946	16,000
Exercise of conversion options		-	(11,976)
Disposal		(4,015)	-
Changes in fair value		4,061	1,848
Ending balance	₩	185,948	132,956

- (e) Finance Income (Costs)
- (i) Details of finance income (costs) by categories for the nine-month period ended September 30, 2017 were as follows:

		Available -for-sale	Loans	Financial liabilities measured at	
		Financial	and	amortized	
In millions of won		assets	receivables	cost	Total
Profit or loss:					
Interest income	₩	7	29,457	-	29,464
Dividend income		12,744	-	-	12,744
Investment income on long-term					
deposits in MSA Escrow Fund		-	4,606	-	4,606
Gain on sale		1,014	-	-	1,014
Interest expense		-	-	(739)	(739)
Impairment loss		(18,167)	(3,437)	-	(21,604)
	₩	(4,402)	30,625	(739)	25,484
Other comprehensive income before tax					
Net change in fair value	₩	21,922	-	-	21,922
Reclassification adjustments on sale		(1,014)	-	-	(1,014)
Reclassification adjustments on impairment		18,167	-	-	18,167
	₩	39,075	-	-	39,075

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

31. Risk Management and Fair Value of Financial Instruments, Continued

- (e) Finance Income (Costs), Continued
- (ii) Details of finance income (costs) by categories for the nine-month period ended September 30, 2016 were as follows:

In millions of won		Available -for-sale Financial assets	Loans and receivables	Financial liabilities measured at amortized cost	Total
Profit or loss:					
Interest income	₩	22	26,926	-	26,948
Dividend income		11,446	· -	-	11,446
Interest income on long-term					
deposits in MSA Escrow Fund		-	3,554	-	3,554
Gain on conversion of					
redeemable convertible preferred shares		-	311	-	311
Interest expense		-	-	(503)	(503)
	₩	11,468	30,791	(503)	41,756
Other comprehensive loss before tax					
Net change in fair value	₩	3,035	-	-	3,035

32. Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The board of directors seeks to maintain a balance between the higher returns that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital position.

The Company monitors capital using equity and net debt by deducting cash and cash equivalents and current financial instruments from borrowings. The Company applied the same capital management strategy that was applied in the previous year.

As of September 30, 2017 and December 31, 2016, the Company's equity and net debt are as follows:

In millions of won		September 30 2017	December 31 2016
Debt (borrowings)	₩	2,790	3,851
Less:			
Cash and cash equivalents		(1,143,361)	(688,735)
Current other financial assets		(1,260,000)	(1,620,000)
Net debt (asset)		(2,400,571)	(2,304,884)
Equity	₩	6,939,676	6,578,897

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

33. Contingent Liabilities and Commitments

- (a) Each year the Company deposits a proportion of sales of tobacco products in the United States in accordance with the Tobacco Master Settlement Agreement ("MSA") under the Escrow Statute of the United States government. The MSA Escrow Funds are maintained to pay the medical expenses of tobacco purchasers who have suffered health effects as a result of smoking. The unused portion of this fund will be refunded to the Company 25 years from the date of each annual funding. The Company recorded as long-term deposits the amounts paid into the MSA Escrow Funds of State governments in the United States against potential litigation and damages related to the export of tobacco into the United States.
- (b) As of September 30, 2017, a lawsuit by National Health Insurance Service claiming damages of \(\forall \) 53,742 million has been filed against the Company. Additionally, as of September 30, 2017, the Company is involved in eight lawsuits as a plaintiff for alleged damages totalling \(\forall \) 25,350 million and three lawsuits as a defendant for alleged damages totalling \(\forall \) 1,806 million. The amount of the liability the Company may ultimately be liable for with respect to the litigation cannot be reasonably estimated as of September 30, 2017.
- (c) As of September 30, 2017, the Company has entered into letter of credit agreements with KEB Hana Bank and other bank with limits in the aggregate of USD 57,000 thousand.
- (d) As of September 30, 2017, the Company's trade receivables from the export of cigarettes are insured against non-payment up to USD 24,813 thousand by short-term export insurances with the Korea Trade Insurance Corporation.
- (e) The Company has been provided with a foreign currency payment guarantee for local dealers in Russia and other countries up to USD 40,000 thousand and USD 20,000 thousand by KEB Hana Bank and Westchester Fire Insurance Company. Details of guarantees exercised as of September 30, 2017, are summarized as follows:

In thousands of USD, THB and millions of IDR		Exercised amount
Customs bond and L/C opening of KT&G USA Corporation Performance guarantee for export of tobacco sheet to Thailand Tobacco Monopoly Payment guarantee for purchase of certificate stamp of PT Mandiri Maha Mulia, etc.	USD THB IDR	31,417 11,675 79,424

- (f) On March 17, 2011, the Company signed the memorandum of understanding ("MOU") on global investment partnership with National Pension Service to jointly invest in foreign assets with a limit of \(\frac{\text{W}}{800,000}\) million.
- (g) As of September 30, 2017, the Company has been provided with guarantees of USD 1,433 thousand from TRAVELERS CASUALTY AND SURETY COMPANY OF AMERICA for the execution of escrow deposits.

Notes to the Separate Interim Financial Statements (Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

33. Contingent Liabilities and Commitments, Continued

(h) With relation to the acquisition of KT&G Life Sciences Corporation, the Company entered into a contract with a former owner of the acquiree, Gwak, Tae-Hwan ("Individual Shareholder"). Details of the contract are as follows:

Description	Details
Restriction of disposal	Individual Shareholder shall not be permitted to dispose of its shares, in whole or in part, within one year after KT&G Life Sciences Corporation is listed.
Right of first refusal held by the Company	Individual Shareholder shall not be permitted to make any transfer of its shares, in whole or in part, unless Individual Shareholder has offered them first to the Company.
Tag-along right held by Individual Shareholder	In the event that the Company proposes to enter into a transaction or a series of related transactions with a third party purchaser to dispose of its shares, then Individual Shareholder shall elect to participate in such disposition upon the terms and conditions no less favorable than those applicable to the Company.

- (i) As of September 30, 2017, the Company has provided guarantees up to \(\frac{\pma}{2}\)37,516 million with an exercised amount of \(\frac{\pma}{1}\)94,483 million for the buyers of apartments in respect of their borrowings from Shinhan Bank.
- (j) As of September 30, 2017, the Company is insured by performance bond insurance up to \text{\text{\$\psi}4,061} million with the Seoul Guarantee Insurance.
- (k) As of September 30, 2017, the Company recognizes other financial assets of \(\preceq\)6,340 million deposited in Nonghyup bank and restricted in use in order to provide a performance guarantee for the commercial district development project in Sejong-si.

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

34. Cash Flows

(a) Details of cash generated from operations for the nine-month periods ended September 30, 2017 and 2016 were as follows:

In millions of won		2017	2016
Profit for the period	₩	786,072	738,004
Adjustments for:		, , , , , ,	, , , , ,
Income tax expense		256,466	236,406
Finance costs		18,906	503
Finance income		(117,633)	(44,135)
Depreciation		77,350	78,644
Amortization		28	15
Retirement and termination benefits		26,023	23,606
Foreign currency translations loss		31,883	60,441
Impairment loss on trade and other receivables		3,437	586
Write-down of inventories		838	178
Loss on sale of property, plant and equipment		320	897
Loss on sale of intangible assets		3,121	8
Loss on disposal of investments in subsidiaries		8,945	-
Other expense		7,345	2,087
Foreign currency translations gain		(7,755)	(114)
Gain on sale of property, plant and equipment		(4,641)	(11,903)
Gain on sale of intangible assets		(595)	-
Gain on sale of investment in associates and joint ventures		(19)	(6,095)
		1,090,091	1,079,128
Changes in working capital:			
Trade and other receivables		(185,063)	(135,509)
Advance payments		(21,769)	(16,756)
Prepaid expenses		4,347	2,136
Prepaid tobacco excise and other taxes		86,087	8,278
Inventories		153,557	62,716
Trade and other payables		(40,557)	17,035
Advance receipts		(478)	(23,784)
Tobacco excise and other taxes payable		(37,180)	(92,793)
Payment of retirement and termination benefits		(8,722)	(7,706)
Cash generated from operations	₩	1,040,313	892,745

Notes to the Separate Interim Financial Statements

(Unaudited)

For the nine-month periods ended September 30, 2017 and 2016

34. Cash Flows, Continued

(b) Details of material transactions without cash inflow and outflow for the nine-month periods ended September 30, 2017 and 2016 were as follows:

In millions of won		2017	2016
In-kind donation of treasury shares	₩	-	19,200
Acquisition of investment in subsidiaries			
resulting from the conversion of redeemable convertible preferred shares		-	27,415
Decrease in accrued expenses			
related to payment of retirement and termination benefits		(2,430)	(1,452)
Increase (decrease) in other payables			
related to acquisition of property, plant and equipment		(659)	896
Increase (decrease) in advance receipts related to disposal of			
property, plant and equipment and non-current assets held for sale		-	(422)
Increase (decrease) in other receivables related with disposal of			
property, plant and equipment and non-current assets held for sale		(3,593)	3,129
Reclassification of available-for-sale to loans		2,054	-
Acquisition of investment in subsidiaries due to conversion of loans		47,490	-

⁽c) The Company presented cash flows arising from short-term financial instruments on a net basis.